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Abstract 
Thiol and purine compounds are widely distributed in nature. They are involved in 
physiological processes, such as, homeostasis and redox signalling, and disturbances of these 
functions are the basis of many human diseases. Therefore, there has been a great effort to 
better understand the metabolomics of these compounds.  
The goal of the present work was to optimize an Ultra-High Performance Liquid 
Chromatography method for simultaneous detection and quantification of some thiol, and 
purine compounds in cells lysates and biological fluids.  
For this purpose, an UPLC® system, equipped with an HSS T3 column, with 
fluorescence and photodiode array detection was used. Preliminary experiences to optimize 
chromatographic separation of standard compounds were accomplished and involved testing 
of conditions for sample pre-analytical treatments, mobile phase compositions and detection 
conditions.  
A good resolution and separation was obtained for the standards tested. The thiols 
Glutathione, Cysteine and Homocysteine eluted at 0.655  0.005, 2.189  0.000 and 3.752  
0.001 minutes. Intra-day precision of the method was 12.05, 9.87 and 9.06% for areas. Farther, 
inter-day precision for the retention times were 29.49, 1.63 and 2.24% and for areas were 
41.55, 28.28 and 29.46%, respectively. Purines Adenosine and Inosine eluted at 2.249  0.001 
and 2.584  0.005 minutes. Inter-day precision for the retention times were 0.06 and 0.01% 
and for areas were 6.99 and 6.63%, respectively. Linearity was tested in a range of 
concentrations from 5 to 100 M for thiols and 25 to 500 M for purines, with good results. 
Additionally, the detection and quantification limits were too high. Unfortunately, our analyses 
do not shown intra or inter-day precision. Therefore, the validation was not completed 
because reproducibility was inconsistent due to the mechanical failure of the chromatographic 
equipment used. However, we concluded that the identification of these analytes is possible 
with the methods established. 
 
Keywords: Thiols; Purines; Ultra-High Performance Liquid Chromatography; Oxidative stress. 
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Resumo 
Os compostos tiólicos e as purinas encontram-se amplamente distribuídos na natureza. 
Estão envolvidos em vários processos fisiológicos, como a homeostasia e a sinalização redox. 
Perturbações destas funções estão na base de muitas patologias humanas. Por essa razão, 
existe um grande esforço da comunidade científica para entender estes compostos, 
particularmente ao nível da metabolómica. 
O objetivo deste trabalho foi otimizar um método de cromatografia líquida de ultra 
precisão para a deteção e quantificação destes compostos, em lisados celulares e fluidos 
biológicos. 
Com este propósito, foi usado o sistema cromatográfico UPLC®, equipado com uma 
coluna HSS T3 acoplado a detetores de fluorescência e fotodiodos em série para os tióis e 
purinas, respetivamente. Foram realizadas diversas experiências preliminares de otimização da 
separação dos padrões, onde foram testadas várias condições de pré-tratamento das amostras, 
diversas composições das fases móveis e condições de deteção. 
Foi possível obter uma boa resolução com os compostos tiólicos e com as purinas. O 
Glutatião, a Cisteína e a Homocisteína eluíram aos 0.655  0.005, 2.189  0.000 e 3.752  
0.001 minutos. A precisão inter-diária dos tempos de retenção foi de 29.49, 1.63 e 2.24% e das 
áreas foi de 41.55, 28.28 e 29.46%, respetivamente. A linearidade do método foi testada numa 
gama de concentrações entre 5 e 100 M, com bons coeficientes de correlação. Os compostos 
purínicos Adenosina e Inosina eluíram aos 2.249  0.001 e 2.584  0.005 minutos. A precisão 
inter-diária dos tempos de retenção foi 0.06 e 0.01% e das áreas 6.99 e 6.63%, respetivamente. 
A linearidade do método foi testada numa gama de concentrações entre 25 e 500 M, com 
bons coeficientes de correlação. Infelizmente os resultados foram inconsistentes e a validação 
não foi alcançada, devido a falhas mecânicas do equipamento cromatográfico utilizado. 
Conclui-se que a identificação dos analitos é possível com os métodos estabelecidos. 
 
Palavras-chave: Tióis; Purinas; Cromatografia em fase líquida de ultra performance; Stress 
oxidativo 
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Aims 
The project presented in this thesis had as the main purpose to obtain a master's 
degree in Applied Biochemistry. This work was developed in the Centro de Química (CQM) of 
the University of Madeira. 
 
Specific objectives 
In this dissertation, an extensive bibliographic search and laboratory research were 
performed. The theoretical introduction highlights all relevant information for the 
development, analysis and discussion of the experimental work.  
The experimental part consisted of two approaches, developed with the following 
purpose:  
First, developed and optimized a pre-analytical procedures for standard treatment of 
some biomarkers of oxidative stress, for analysis by Ultra-High Performance Liquid 
Chromatography (UHPLC). The optimization procedure was held for the detection of the 
standard glutathione in reduced form (GSH), homocysteine (Hcy), cysteine (Cys) and 
cysteamine (Cyst) with fluorescence (FLR) detection. Additionally, a method of photodiode 
array (PDA) detection for purine compounds analysis, like adenosine (Ado) and inosine (Ino) 
was developed. 
In the second approach, two analytical methods by UHPLC with FLR and PDA detection 
for a high sensitivity quantification of thiols and purines was established and optimized. Finally, 
application in biological samples. 
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Chapter 1  
Introduction 
In this chapter, the most relevant aspects of thiol compounds and their derivatives will 
be reviewed, as biomarkers of oxidative stress. Also, some purine compounds will be 
mentioned, referring and emphasizing cardiovascular pathologies and some of their factors, 
like the unbalance of the physiological and homeostatic state of  endothelial cells. 
Additionally, analytical techniques for their assessment will be focused, including pre-
analitical considerations.  
 
1. Oxidative Stress and Redox Systems 
 The term “stress”, expresses the tension exerted in an organism mediated by a 
physical or chemical injury, which consequently triggers several mechanisms of defense and 
adaptation [1]. Cellular stress is a cause of pathology in certain human diseases, such as, 
hypoxia, immune reactions and infections [2].  
The cell is composed of organelles, small structural units bounded by the membrane, 
which are the basis of their operation and integrity. As such, it can be said that the redox state 
is also divided into compartments, highlighting the mitochondria, the endoplasmic reticulum, 
the nucleus and the cytoplasm, as the main areas of redox signaling. Comparatively, it is in the 
mitochondria, where there is a greater redox activity, since its membrane has five multiprotein 
complexes, which are responsible for the oxidative phosphorylation. These are the NADH-
quinone oxidoreductase, succinate dehydrogenase, coenzyme Q cystochrome reductase, 
cytochrome oxidase and ATP synthase [3].  
In cell metabolism, it is possible to find different redox systems, such as, the pairs 
flavine adenine dinucleotides (FADH2/FAD), nicotinamide adenine dinucleotides (NADH/NAD+ 
and NADPH/NADP+), thioredoxins (TrxRed/TrxOxi) and glutathiones (GSH/GSSG) [4, 5]. They 
promote a dynamic regulation that maintains the cells in good oxy-reductive conditions, by 
balancing the concentrations of each coupled form [6].  
Under normal conditions, the formation and neutralization of the reactive oxygen (ROS) 
and nitrogen (RNS) species and all the species listed in table 1, are counterbalanced by the 
above antioxidant systems [7].  
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Table 1 - Different reactive species that are found in organisms, under normal or pathological conditions. 
Adapted from [8 - 10]:  
Reactive Oxygen Species (ROS) Reactive Nitrogem Speies (RNS) 
Superoxide radical (O2●-) Nitrogen dioxide radical (NO2●) 
Hydrogen peroxide (H2O2) Nitrite ion (NO2-) 
Hydroxyl radical (HO●) Nitric oxide radical (NO●) 
Hydroxyl ion (HO-) Nitroxyl ion (NO-) 
Hydroxyl (ROH) Nitroxyl (RNH) 
Hydroperoxide (ROOH) Nitroperoxide (NOOR) 
Lipid peroxyl radical (LOO●) Dinitrogen trioxide (N2O3) 
Lipid hydroxide (LOH) Nitroxide (NOH) 
Lipid hydroperoxide (LOOH) Nitrous acid (HNO2) 
Hydrochloric acid (HOCl) Nitryl chloride (NO2Cl) 
Peroxynitrite radical (ONOO●) 
Peroxynitrite ion (ONOO-) 
Peroxynitrous acid (ONOOH) 
 
Antioxidants are molecules that prevent oxidative reactions caused by ROS and RNS 
occurring with damage effects [7]. The regulation of antioxidant systems is crucial for a proper 
cell function, which is achieved by lowering levels of reactive species. Several studies have 
shown that these systems are important protective agents, because they avoid abrupt and 
irreversible changes on metabolic molecules and irreparable damage of deoxyribonucleic acid 
(DNA), which in turn could induce cell death [4].  
In some physiological conditions, the regulatory mechanisms may not be effective, for 
example, when the levels of antioxidants are very low or nonexistent, or when there is 
absence or inactivation of some of the enzymes involved in those mechanisms [11]. In these 
cases, excess of reactive species compromises the metabolic balance or even the cell viability. 
However, the consequences of these possible situations depend on where it happens, the 
availability of energy and the plasticity of the cells [2]. Therefore, oxidative stress may arise 
and translate into an imbalance between oxidants and neutralizing compounds, leading to 
disruption of the redox signalling, loss of homeostatic control and can consequently, cause 
genetic damage [12]. Therefore, a condition that results from the accumulation of oxidative 
compounds, in detriment of the reducing ones, reduction of the antioxidant agents, or even, 
by synergy of these two situations [13].  
In aerobic metabolism, the inevitable oxygenated status can be a hostile environment, 
what is a contradiction of life. The oxygen molecule (O2) is essential in the respiration process 
and energy metabolism but, at the same time, is the pathogenic basis of many diseases or 
degenerative conditions of living beings. The theoretical principle, states that a single 
inspiration contains O2 capable of producing billions of reactive species that may have signaling 
or destructive action [14]. However, the cells have antioxidant compounds and enzymes that 
develop protection strategies, which are effective pathways adapted to survival, in this 
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oxygenated and stress conditioned environment [12]. Still, there is always a chance of 
something going wrong, at metabolic level, and oxidative damage may arise. 
Accordingly, the main consequences of oxidative stress are the molecular changes in 
nucleic acids, lipids and proteins that compromise cell stability or even, viability [15]. Thus, in 
extreme cases, the cell promotes secondary responses to induce death by necrosis or 
apoptosis. Moreover, in most fortunate cases, the cell is able to restore the redox homeostatic 
state and the metabolism back to be in equilibrium without negative consequences [11].  
 
1.1. Oxidative Stress and Endothelial Cells 
 The endothelial cells (EC) line on the entire surface of the vascular system, forming a 
barrier between the blood and the other organs. It is a versatile and multifunctional monolayer 
that is essential in the structural support and integrity of the vascular wall throughout all 
circulation system. These are cells with high metabolic activity, with endocrine, paracrine and 
autocrine functions. They form a dynamic and semi-permeable barrier, which controls the 
transport of a large number and variety of metabolites between the different tissues [16]. In 
its metabolic properties, regulation of the vascular tone that is characterized by the normal 
state of firmness and elasticity of an organ or tissue, through the production of vasodilator and 
vasoconstrictor molecules, stands out. At this level, the control of the flow and blood clotting 
happens by the action of platelet factors and regulation of inflammatory responses [17].  
Under physiological conditions, EC express and secrete a number of specific metabolic 
compounds in response to different stimulations. Among the activating molecules, we present 
some of those that stand out in the anticoagulant reactions, such as, prostacyclin (PGI2), nitric 
oxide (NO), thrombomodulin (TM) and plasminogen tissue activator (PLAT); the latter, also 
presents pro-coagulant action; the vasodilators NO, PGI2 and endothelin, and the 
vasoconstrictors endothelin, thromboxane and prostaglandins [18, 19]. Furthermore, EC 
mediate vascular proliferation (angiogenesis) in synergy with platelets, smooth muscle cells 
and the matrix constituents (fibronectin, laminin, collagen and proteoglycans) [20, 21].  
A relevant fact, is that the growth and survival of EC depend on the intracellular 
production of reactive species, such as, superoxide anion (O2●-) and hydrogen peroxide (H2O2), 
as they are responsible for the activation of certain essential metabolic proteins, such as, 
mitogenic kinases (ERK1/2 MAPK) and vascular endothelial growth factors (VEGF) [22]. In 
addition, their circulation integrity results from the action of thrombin and adenosine 
diphosphate (ADP) in synergy with the changes of pressure and blood flow, which in turn 
induce the secretion of prostacyclin, NO and vasoactive substances that inhibit platelet 
aggregation and cause vasodilation [20]. Futhermore, an inflammatory response outcome 
from damage on the vascular endothelium, leads to multiple hemodynamic changes, such as, 
dilation, increased blood pressure and segregation of specific mediators, in order to inhibit and 
repair the injury [23]. Thus, it is understandable that cell barrier disruptions are the source of 
certain pathological states in the cardiovascular system. 
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The syndrome of endothelial dysfunction is a disorder that expresses vascular 
abnormalities, which are the consequence of damage in the thrombogenic and angiogenic 
properties. This may result from loss of tone by the vascular smooth muscle or, from blocking 
of the normal immunologic response [24]. This disturbance is characterized essentially by 
reduced NO bioavailability and production. Also, by increased adhesion of monocytes and 
polymorphonucleate cells, cholesterol and oxidized low-density lipoprotein (LDL) accumulation, 
signaling failure of endothelium derivatives, expression of pro-fibrotic genes and premature 
cell senescence or apoptosis [24, 25].  
 Risk factors of oxidative stress and endothelial dysfunction are classified as i) 
behavioral, such as, smoking, malnutrition, physical inactivity and obesity, and ii) biological 
determinants, like gender, aging, dyslipidemia, hypertension, diabetes, family history and 
genetic defects [26, 27]. These factos affect functional integrity of the endothelium, and 
should always be taken into consideration at the clinical level.  
The endothelial health is balanced (figure 1) by damage factors and regenerative 
capacity [28]. In the cardiovascular system, the regeneration is promoted by a decrease in the 
inflammatory response, which is achieved by reducing cell interactions, such as, decreasing 
macrophage phagocytosis of LDL, secreting platelets and inhibiting foam cells formation [29]. 
That balance is also promoted by the circulating endothelial cells (CEC), which derive from the 
endothelial layer of vessels, and by the circulating endothelial progenitor cells (CEPC) from 
bone marrow, in the bloodstream [28]. These cell types are major promoters of the integrity, 
are responsible for angiogenesis and regeneration of the endothelium. Therefore, they 
prevent, attenuate or delay the development of atherosclerosis and improve the blood flow 
[29].  
 
Figure 1 - Counterbalancing of endothelial damage with the regenerative capacity. Image obtained from 
Fadini et al. [28]. 
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1.2. Biomarkers of Oxidative Stress  
The term biomarker features a measurable compound as an indicator of normal 
biological metabolism, pathological conditions or pharmacological responses to therapeutic 
processes [30]. Therefore, a biomarker should help in symptomatic or pre-symptomatic 
disease diagnosis and provide data results showing the clinical effectiveness of treatments [15]. 
In theory, to be validated as a biomarker of oxidative stress, a compound must have the 
following characteristics: i) be stable, not susceptible to oxidative induction or loss due to 
handling, processing, analysis or storage; ii) be the main product that is directly involved in the 
initiation or progression of the pathological condition; iii) be accessible on the target tissue and 
quantitatively translate the metabolic changes [30]; iv) be a significant product present in high 
concentrations and free of confounding factors, such as from diet; v) be identified and 
quantified by noninvasive and painless methods; vi) its analysis must be specific, sensitive and 
reproducible [30]; vii) be easy to detect and quantify between populations; viii) have relatively 
stable concentrations, which do not vary widely in the same person, in different times and 
conditions; ix) be measurable with relatively small variation in intra and inter sample tests [30].  
Validation requires multiple steps that are often difficult to achieve, because of the 
complexity of the metabolic pathways.  
 
Measurement of oxidative stress and antioxidant defense biomarkers is a major 
challenge in research studies. Next, the most relevant topics for each thiol and purine 
compound analyzed in this dissertation are presented, including properties, functional 
characteristics, metabolic and regulatory pathways, as well as, some pathological associations. 
Finally, the relationship and metabolic link between them is showed. 
 
1.2.2. Thiol Compounds 
Thiol compounds and their derivatives are widely distributed in nature, either in 
prokaryotic or eukaryotic cells, in plant and animal tissue [31]. These compounds are 
synthesized and then sent to the required locations, where they are essential for the proper 
functioning of organisms. Thiols are involved in crucial physiological processes that include 
elimination of toxins, redox signalling, transport, metabolic storage and protein functionality, 
as well as, gene expression, proliferation, differentiation and even in cell death [32]. Several 
studies have shown that the maladjustment of these roles is the basis of many human diseases, 
which is why there is a great effort of the scientific community to better understand their 
metabolic implications.  
Thiol compounds and their derivatives are important scientific targets, because they 
are ubiquitous and critical in many physiological processes. Several studies have been carried 
out in different biological samples trying to demonstrate that they are the basis of many 
human pathologies and their importance as biomarkers at clinical and pharmacological levels 
has been shown [33]. They are low molecular wietgh compounds, considered below 900 Da 
[34]. In their structure there is one (or more) sulfhydryl groups (R-SH), sulphur and hydrogen 
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linked to a carbon atom, also known as thiol or mercaptan group. The R-SH group is analogue 
to alcohol group (R-OH) but form weaker hydrogen bonds. Therefore, these compounds are 
volatile [35], highly polar, soluble in water and with low boiling points [36]. The sulfur (S) is an 
abundant non-metal atom, which can be incorporated into molecules, giving rise to sulfate or 
be reduced to sulfite, the main substrate in cysteine synthesis [37]. Thiol group is considered 
to be the most reactive group present in cells. Actually, it is involved in many metabolic 
reactions that depend on the oxidative capacity, a specific biochemical property that 
distinguishes them from other molecules with metabolic functions [37]. In figure 2 the most 
relevant organic sulfur compounds in cell metabolism, are highlighted. 
The thiolate anions (R-S-) are more reactive than the sulfhydryl group, becouse they 
are easily oxidized to different products, such as, sulfenic acid (R-SOH), sulfinic acid (R-SO2H) 
and sulfonic acid (R-SO3H) [7]. The sulfite compound is less reactive than the thiol that gives 
rise to it, but it is extremely important in the stability of protein complexes, in polypeptide 
chains with tertiary and quaternary three-dimensional structure, as well as, in the functionality 
of the active site of some metabolic enzymes. The biosyntheses of organosulfur compounds 
occur mainly in bacteria and plants, while the oxidation commonly occurs in animals [37].  
 
Figure 2 - Different thiol compounds that are present in biological systems. Abbreviations: H2O2, 
hydrogen peroxide; ●NO, nitric oxide; Srx, sulfiredoxin. Image obtained from Ma [7].  
Endogenous hydrogen sulfide (H2S) is considered an important signaling molecule for 
EC and cardiovascular system (Figure 3) [38]. It is produced by enzymatic reactions of 
cystathionase γ-liase (CGL), cystathionine β-synthase (CBS) and 3-mercaptopyruvate sulphur 
transferase (3MST). Subsequently, it suffers different conversions. It may be oxidized to 
hydrosulfide ion (HS-) or thiolsulfate forms, may produce sulfhemoglobin reacting with 
methemoglobin, and can be methylated to methanethiol or dimethylsulfide. It has effects on 
endothelial, but also in smooth muscle and inflammatory cells, at mitochondria and over 
nuclear transcription factors [39]. It is considered a toxic molecule, but it also has beneficial 
effects in blood pressure control and regulation of inflammation. 
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Figure 3 - Cardiovascular functions of hydrogen sulfide (H2S). Abbreviations: H2O2, hydrogen peroxide; 
3MST, 3-mercaptopyruvate sulphur transferase; SH-, hydrosulfide ion; H+, free hydrogen cation; CAT, 
cysteine amino transferase; CGL, cystathionase γ-liase. Image obtained from Calvert et al. [38].  
According to its concentration, H2S (ranging from 10 to 100 µM [38]) can produce 
cytoprotection actions, through i) protein modifications (S-sulfhydration); ii) modulation of ion 
channels, such as, vascular KATP channels, transient receptor potential cation channel (TRPV) 
and calcium channel (L/T-type Ca2+) iii) stimulation of the production of antioxidant molecules, 
like nuclear factors (NrF-2) and glutathione [39]; and iv) decrease of mitochondrial functions 
[40]. The purpose is to prevent oxidative stress, apoptoctic and necrotic mechanisms. In some 
conditions, like in heart failure, administration of H2S has shown to be a promoter of 
remodelling processes [41]. Similarly, in atherosclerosis, this molecule modulates 
vasodilatation or vasoconstriction reactions, inhibits the expression of leukocyte adhesion 
molecules and formation of foam cells. In addition, it activates pro-angiogenic mechanisms, 
prevents edema formation and it is an anti-apoptotic mediator [39]. This is a compound 
related to the thiol homocysteine, and its metabolic importance will be specified further on. 
Also important in this group of thiol compounds, are some amino acids, which have 
been implicated in the pathophysiology of a wide range of chronic conditions [42]. As a matter 
of fact, sulphur amino acids like methionine (Met), homocysteine (Hcy) and cysteine (Cys) are 
being investigated as potential indicators of health status and disease risk. Glutathione, the 
most abundant mammalian antioxidant, a tripeptide that is linked to Hcy metabolism via the 
transsulphuration pathway, which will be specified later on. 
Some human disorders are associated with increase or decrease of the concentrations 
of thiol compounds and their derivatives, which in synergy with the reactive species cause 
oxidative damage, dysfunction and activation of the vascular endothelium. There are 
numerous disorders related to these conditions, such as, hypertension, heart attack or failure, 
angina, pulmonary hypertension, stroke, peripheral artery disease, macular degeneration, 
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Alzheimer disease, dementia, sleep apnea, renal failure, diabetes, erectile dysfunction, among 
others [43].  
 
1.2.2.1. Glutathione 
In 1888, Rey-Pailhade identified a compound that he called Philothione, a Greek 
expression, which means “sulfur friend”, in yeasts. Later in 1927, he changed the name to 
glutathione (GSH), when Hopkins identified it as a dipeptide of glutamic acid (Glu) and Cys [44]. 
However, in the same year, Hunter and Eagles conducted more studies and realized that there 
was an error [45]. As such, in 1929 [46] the compound was reanalyzed in yeast and 
erythrocytes, and GSH was recharacterized as a tripeptide also composed by glycine (Gly) 
(figure 4). Hopkins [45, 46] noted that, biochemically, this molecule exhibited an exceptional 
behavior, that it was a very unstable compound due to the sulfur atom in the Cys residue. He 
even stated that this instability resided in all molecules formed by Cys or its derivatives, which 
could lead to GSH misidentification [45, 46].  
 
Figure 4 - Representation of the molecular structure of glutathione. 
 
I. Glutathione syntesis 
The thiol compound GSH results from enzymatic reactions, which occur in the 
cytoplasm of cells and extracellular space of all organic tissues (Figure 5). The formation, from 
the constituent amino acids starts with the activation of two ATP-dependent enzymes [47]. 
Initially, the γ-glutamylcysteine ligase (GCL) catalyzes the peptide bond between Glu and Cys, 
creating the dipeptide γ-GluCys. Subsequently, glutathione synthetase (GS) adds Gly amino 
acid, forming GSH [48].  
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Figure 5 – Enzymatic synthesis of glutathione. Abbreviations: ADP, adenosine 5'diphosphate; ATP, 
adenosine 5'triphosphate; GCL, γ-glutamylcysteine ligase; GS, glutathione synthetase; L-Cys, cysteine; L-
Glu, glutamic acid; L-Gly, glycine; Pi, inorganic phosphate; γ-GluCys, gamma-glutamylcysteine; 1. 
Chemical bond between the γ-carbonyl group of glutamic acid and the amine group of cysteine; 2. 
Chemical bond between the α-carbonyl group of cysteine and the amine group of glycine. Adapted from 
Lu [47].  
 The biosynthesis of GSH is initially regulated by gene expression and metabolism is 
further controlled by feedback signaling mechanisms, following homeostatic conditions [49]. 
GSH synthesis is limited by ATP bioavailability and by the catalytic action of GCL and MS 
enzymes. Besides, GCL is inhibited by negative feedback when GSH concentrations reach high 
levels [4].  
In GSH molecule, each amino acid has unique features that are critical in its general 
skills and properties. GSH presents a unique structure due to the binding between Glu and Cys, 
which uses the γ-carbonyl group rather than the typical α-carboxyl bond. This rare union is 
resistant to the endogenous action of peptidases and is only degraded by the gamma-glutamyl 
transpeptidase (GGT) [50]. GGT is an ecto-enzyme, it has an active centre facing the outside 
and a higher affinity for Met, Glu, Cys and arginine (Arg) [51]. Orlowski and Meister [51] 
studied the activity of this enzyme in mice kidney and found that the reactions of GSH 
synthesis and degradation are coupled to major transport ways.  
 
II. Glutathione and the gamma-glutamyl cycle 
Described by Meister in 1970 [51] the gamma-glutamyl cycle represented in figure 6, is 
a key route in the bioavailability of GSH and Cys in the living organism. Meister investigated 
GSH metabolism in mice kidneys and characterized the catalytic reactions of this compound, 
which are associated with the transport of amino acids. He observed that GSH is clived by GGT 
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and, at the same time, the latest mediates the uptake of amino acids by other specific carriers, 
from the extracellular space up to the cytoplasm [51, 52]. So, GGT converts GSH into γ-
glutamylaminoacid (γ-Glu-aa) releasing cysteinylglycine (CysGly), in the extracellular space. 
This dipeptide, suffers degradation by some exopeptidases and their amino acids are provided 
for new metabolic reactions. The γ-Glu-aa is then imported and, in the intracellular space, it is 
catalysed by γ-glutamyl cycle transferase (γ-GGCT), which releases the transported amino acid 
and 5-oxoproline complex. It is then converted to Glu through the action of 5-oxoprolinase (5-
Oxo) [47, 51]. Following the cycle, GSH is regenerated by the subsequent reactions, which have 
already been described and schematized in figure 5.  
GGT is a canalicular enzyme [1], which has been identified through histological studies, 
in the apical surfaces of several epithelial tissues, such as, the cells covering the villi in the 
jejunum, external portion of pancreas, liver, bile, seminal vesicles, epididymis, fallopian tubes, 
ovaries, endometrium, prostatic ducts, submaxillary and mammary glands, ependymal cells of 
the brain and in the endothelium of blood capillaries [51], among others. 
 
Figure 6 - Gamma-glutamyl cycle expressing glutathione metabolism associated with the transport of 
amino acids. Abbreviatons: 5-Oxo, 5-oxoprolinase; aa, amino acid; ADP, adenosine 5'diphosphate; ATP, 
adenosine 5'triphosphate; GCL, gamma-glutamylcysteine ligase; GGT, gamma-glutamyl transpeptidase; 
GS, glutathione synthetase; L-Cys, cysteine; L-Glu, glutamic acid; L-Glu-Cys, glutamylcysteine; L-Gly, 
glycine; Pi, inorganic phosphate; T-GSH, glutathione transporter protein complex; T-X, transporter X; γ-
GGCT, gamma-glutamyl cyclotransferase; γ-Glu-aa, gamma-glutamyl amino acid. Adapted from [47, 51].   
 Therefore, GSH synthesis and catabolism have a number of enzymatic steps regulated 
and controled by specific transporters. GSH degradation occurs exclusively on the surface of 
the cell membrane that has GGT, as mentioned above. GGT is the only ecto-enzyme capable of 
degrading GSH complex (conjugated and oxidized glutathione) [47].  
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In 1970, Meister [51] speculated that the gamma-glutamyl cycle could be crucial for 
metabolic transport and/or secretion and, that the presence of GSH was indispensable. Fifteen 
years later [52], he confirmed that the transport of γ-Glu-aa is one step of the cycle, which 
mediates the uptake of amino acids. He also found that this transport system is inhibited by 
high GSH concentrations in the extracellular space, as well as, low GSH concentrations inside 
the cells [52, 53].  
A limiting factor of GSH synthesis is the bioavailability of Cys [53]. This amino acid is in 
higher concentration in the cytoplasm and, externally, it is more abundant in the oxidized form, 
as cystine (2Cys). Therefore, it seems that cells perform the gamma-glutamyl cycle also as a 
Cys source [54]. However, numerous studies have tried to clarify the uptake of Cys and other 
amino acids by cells, but until now, there is no consensus, because in the several reports, 
different cells were used (for example: astrocytes [55], red blood cells, endothelium or 
epithelium [56]). The uptake of Cys and 2Cys is surely mediated by different carriers, which can 
be coupled or in antiport. It also depends on sodium (Na+) or chlorine (Cl-) ions. However, all 
studies confirm that the transport of amino acids is an important feature in antioxidant 
defence mechanisms, as induced by GSH [57, 58].  
 
III. Glutathione oxidation pathway 
GSH is a molecule with a high redox potential [4]. In certain physiological conditions, it 
may be in the reduced (GSH) or in the oxidized (GSSG) tripeptide form (Figure 7). The latter, 
results from the intermolecular binding of two reduced forms by a bisulfite bond (GH-S-S-GH), 
a reaction that is mediated by direct oxidation of ROS or by enzymatic action of glutathione 
peroxidase (GPx) a key selenoprotein [4, 59].  
  
Figure 7 - Representation of the molecular structure of oxidized glutathione. 
The reduced form GSH is mainly responsible for maintaining the redox state in optimal 
levels, contributing to proper cell function, since 90% of total GSH is in this form. The 
GSH:GSSG ratio is maintained by synergy of all metabolic pathways: synthesis, enzymatic 
reduction of GSSG and external degradation of GSH forms [60]. Glutathione reductase (GR) is 
the enzyme responsible for maintaining a constant balance of the pair GSH:GSSG, a critical 
feature in living beings [4]. While GR uses NADPH in the conversion of GSSG to GSH, oxygen 
free radicals convert GSH back into GSSG [61], as shown in figure 8. In addition, GSH can form 
conjugates (GS-R) by association to proteins. Therefore, overall GSH levels are balanced 
between production and consumption [53].  
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Figure 8 - Oxidation and reduction reactions of glutathione. Abbreviations: H+, free hydrogen cation; H2O, 
water; H2O2, hydrogen peroxide; GPx, glutathione peroxidase; GR, glutathione reductase; GSH, reduced 
glutathione; GSSG, oxidized glutathione; NADPH, nicotinamide adenine dinucleotide phosphate reduced; 
NADP+, nicotinamide adenine dinucleotide phosphate oxidized. Adapted from Lushcak [4].  
 
IV. Physiological levels of glutathione 
GSH is present in all types of cells. GSH total concentration, quantified on plasma 
samples, ranges from 2 to 20 µM [62] and inside cells varies between 0.1 and 10 mM [63]. 
These values depend on the type of tissue cell and the overall homeostatic conditions 
displayed. For instance, in neurons it is approximately 2.5 mM and in astrocytes about 3.8 mM 
[53]. Intracellular GSH is in the millimolar (mM or mmol/L) range and extracellularly it is in the 
micromolar (µM or µmol/L) range. GSH levels decrease with increasing transpeptidation [64].  
Quantification is not accurate so far. However, it is estimated that cells have three 
major GSH reservoirs, which are 80 to 85% in the cytoplasm, about 10% in the mitochondria 
and a small percentage in the endoplasmic reticulum [47, 48]. It is considered that 99.5% of 
the circulating GSH is linked to the red blood cells [65] and, in the extracellular space, the 
concentration is very low, because is rapidly metabolized. In 1980, Wendel and Cikryt [66] 
performed an in vivo experiment and determined that, in human plasma, the halt-life time of 
GSH is around 1.6 minutes. It is important to note that GSH concentrations are different 
between tissues due to its functions. In accordance, there is a higher concentration in the liver. 
However, it also depends on the prevalence of some pathological conditions. 
 
V. Specific functions of glutathione 
GSH is a multifunctional molecule. Hence, it interferes with metabolic pathways that 
are vital to cells [67]. Until now, it has been associated with numerous functions and others are 
still being evaluated. GSH chemical structure is the main determinant of the biological roles 
that it plays. This compound has two structural features, the gamma-glutamyl bond and the 
sulfhydryl group, which are closely linked to the performed functions [49]. We can say that 
GSH functions are linked to the antioxidant defense and regulation of some metabolic 
pathways. It is involved in a variety of reactions that emphasize its protective action: i) 
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elimination of ROS and ERN; ii) detoxification of endogenous and exogenous toxins [68]; iii) 
maintenance of normal levels of essential thiols, for proteins synthesis and other molecules, 
such as vitamin C and E; iv) control of Cys storage; v) mediation of copper and iron ions 
transfer [69]; vi) intervention in hormone metabolism, like prostaglandins, estrogen and 
leukotriene [4]; vii) mediation of ribonucleotides reduction both in DNA synthesis and signal 
transduction, by enzymatic regulation; viii) regulation of mitochondrial function and integrity 
[70, 71]; ix) control of cell proliferation and apoptosis [4].  
Some of the above functions are here specified: 
Detoxification - The detoxifying action mediated by GSH is translated in the 
mercapturic acid pathway [72], shown in figure 9. It consists of a sequence of reactions that 
neutralize and eliminate toxic compounds and their metabolic derivatives, harmful to cells. 
This protection mechanism begins with the conjugation of GSH with xenobiotic (X) molecules, 
by a spontaneous reaction or, it may be mediated by glutathione S-transferase (GST) enzyme, 
which produces glutathione conjugates (GS-X) [47]. Subsequently, the conjugate compounds 
are transported across the membrane by the human multidrug resistant-associated protein 
(MRP), an ATP-dependent complex. Outside the cell, they are degraded by the GGT enzyme 
followed by the action of peptidases, giving rise to a conjugate of cysteine (C-X). This comes 
later into the cell, where it is acetylated to mercapturic acid by N-acetyl transferase enzyme, or 
is transformed into a very reactive thiol compound, by the action of β-liase enzyme [47, 72].  
Therefore, the resulting compounds are polar and highly hydrophilic, which facilitates their cell 
transportation and elimination. In this way, GGT is an enzyme that protects cells from 
potentially mutagenic and carcinogenic compounds.  
 
Figure 9 - Detoxification pathway mediated by glutathione. Abbreviatons: ADP, adenosine 
5'diphosphate; ATP, adenosine 5'triphosphate; CG-X, conjugate cysteinylglycine; C-X, cysteine conjugate; 
Glu, glutamic acid; Gly, glycine; GSH, reduced glutathione; GST, glutathione S-transferase; GS-X, 
conjugate glutathione; MRP, protein complex of transporter; NAC-X, mercapturic acid; Pept, peptidase; -
S-X, conjugated thiol; X, toxic compound; γGT (or GGT), gamma-glutamyl transferase. Image obtained 
from Ramsay et al. [72]. 
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Elimination of reactive species - In living organisms, over 90% of the O2 consumed is 
directly reduced to H2O by the electron transport chain, at the mitochondrial membrane of 
cells, with the purpose of producing energy in ATP form [3]. The remaining O2 is reduced, as 
shown in figure 10, by elimination of an electron, giving rise to O2●-. After this, an electron is 
removed and two hydrogen cations (H+) are accepted, forming H2O2. The latter, accepts an 
electron, dividing in a hydroxyl radical (HO●) and a hydroxyl anion (HO-), which subsequently, 
produce water [11, 49]. Therefore, this is one of the means responsible for the emergence of 
ROS and free radical (R●) compounds.  
The amount and types of species that are generated depends on the physiological 
state of the organism [3]. It is important to note, that ROS are important signaling molecules, 
whose action can have negative or positive consequences. It depends on the time and 
intensity of the products, which can mediate an adaptive or a pathological condition [73]. 
Therefore, low levels of ROS favour cell proliferation, intermediate levels can lead to 
senescence and high concentrations may induce cell death by apoptosis or necrosis. 
The mechanisms that regulate ROS levels arise not only by direct elimination, but also 
by the anti-oxidation systems, where low molecular weight compounds like GSH, intervene. 
Proteins with enzymatic activity, such as, glutathione peroxidase (GPx), glutaredoxin (Grx), 
peroxiredoxins (Prx) and thioredoxin reductase (TrxR) are associated to those systems [3, 5].  
For example, GSH and Trx are involved in the electron transport chain, in an antioxidant 
pathway of mitochondria [74]. Moreover, the GSH:GSSG pair relies on the availability of each 
molecule, since glutathione is synthesized in the cytoplasm and is then targeted to the 
organelles. So, transport is a crucial process [47]. In figure 10 the reaction mediated by 
peroxide dismutase (SOD), which catalyses the reduction of O2●- originating H2O2 and catalase, 
is represented. The scheme shows the reduction of H2O2 by GPx coupled to GSH, originating 
H2O and GSSG [4, 11]. In addition, the oxidation products from fatty acids and phospholipids, 
like lipid hydroperoxides (LOOH) and nitro hydroperoxides (NOOH), which are neutralized by 
GSH associated to GPx or GST, are also shown. Similar protective actions can be mediated by 
GSH over the RNS compounds, like the peroxynitrites (ONOO-) [11].  
In order to maintain GSH levels available for the reduction of ROS, the oxidative form 
GSSG is constantly regenerated by GR through the reaction shown in figure 5. 
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Figure 10 - Synthesis and neutralization of reactive species. Abbreviatons: e-, free electron; GPx, 
glutathione peroxidase; GR, glutathione reductase; GS●, glutathione radical; GSH, reduced glutathione; 
GSSG, oxidized glutathione; GST, glutathione S-transferase; H+, hydrogen cation; H2, free hydrogen; H2O,  
water; H2O2, hydrogen peroxide; HNE, 4-hydroxynonenal; HO●, hydroxyl radical; LOH, lipid hydroxide; 
LOOH, lipid hydroperoxide; NADP+, nicotinamide adenine dinucleotide phosphate oxidazed; NADPH, 
nicotinamide adenine dinucleotide phosphate reduced; NOH, nitroxide; NOOR, nitroperoxide; O2, 
oxygen; O2●-, superoxide radical; ROH, alcohol; ROOH, hydroperoxide; SOD, dismutase peroxide. 
Adapted from [4, 11].  
 
VI. Oxidative stress and glutathionylation  
GSH is seen as the main cellular redox buffer. Therefore, the detection and 
quantification of the GSH:GSSG ratio has been considered an important indicator of the redox 
state of cells [75]. In case of oxidative stress, protein modifications mediated by GSH molecules 
emerge, being called glutathionylation. These are considered important functional changes, 
which are responsible for metabolic, transcriptional and signalling processes [76]. That 
reaction is also a way to prevent the loss of GSH, by cellular exportation of the GSSG form (in 
case of oxidative stress, where GSSG is accumulated).  
The Cys residues from protein complexes suffer oxidative modifications, mediated by 
the presence of reactive species and GSH, which result in the formation of the different 
organic sulfur compounds, previously mentioned. In figure 11A, it is possible to verify that in 
the presence of ROS, thiol protein compounds (highlighted in red) can be oxidized to sulfenic, 
sulfinic or sulfonic, and even induce intra or intermolecular modifications. In addition, when 
the oxidation involves RNS, S-nitrosylated proteins emerge [77]. Each of these changes can 
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have positive (activation) or negative (inhibition) consequences in signaling, regulation and 
protein functionality of cells, particularly in proteins with enzymatic action [76]. At this level, 
the presence of GSH and the reaction of glutathionylation (Figure 11B) are decisive in redox 
regulation [77], and we emphasize the reversibility and specificity of this reaction. 
 
Figure 11 - Oxidative modifications of the thiol containing in proteins (A) and the glutathionylation 
reaction (B). Abbreviatons: GPx, glutathione peroxidase; GS(O)SG, glutathione disulphide S-monoxide; 
GS●, glutathione radical; GSH, reduced glutathione; GSNO, S-nitrosoglutathione; GSOH, glutathione 
sulphenic acid; GSSG, oxidized glutathione; NRS, reactive nitrogen species;  ROS, reactive oxygen species. 
Adapted from Dalle-Donne et al. [77]. 
These post-transcriptional modifications, which occur in protein complexes and rely on 
redox reactions are important in the cell-based mechanisms, such as, gene expression, protein 
signaling, energy metabolism, ionic transport, protein folding, degradation and even in cell 
death and survival [78, 79]. On the one hand, it appears that proteins with thiol groups should 
be in a reduced state, because it facilitates their transport and mobilization. On the other hand, 
changes that occur in sulfur residues are crucial in cell signalling or protein activation. Hence, 
dysregulation of redox balance or protein glutathionylation may give rise to human pathology. 
 
VII.  Glutathione and pathological relationship  
GSH deficiency manifests itself mainly through an increase in susceptibility to oxidative 
stress. Moreover, high levels of GSH increase the antioxidant capacity and the resistance to 
damage.  
Some pathological conditions are associated with genetic abnormalities affecting 
enzymes involved in GSH metabolism [53]. There are several mutations and inborn deficiencies 
like those related to GCS, GS, GR, GST, 5-oxoprolinase and GPx enzymes, but the pathological 
pictures are complex and remain unclear [80]. Thus, genetic modifications usually result into 
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enzyme deficiency, inhibition or inactivation (truncated/non-functional or destabilized/short-
lived enzymes) that leads to metabolic dysregulation [81].  
As mentioned previously, on the one hand the presence of ROS is one of the 
determinant factors in endothelial activation and that leads to the emergence of 
atherosclerosis. On the other hand, GSH is a crucial antioxidant compound, and disturbance of 
its metabolism may also promote this disease. Some studies have shown this relationship, as 
held by Ashfaq et al. [82], where they proved that the GSH:GSSG ratio is a novel biomarker 
that helps prevent the onset of atherosclerosis, through early detection. Also, Lapenna et al. 
[83] analyzed mammary arteries in a normal state and with atherosclerotic plaques. They 
observed that in the plaque condition there was no activity of GPx enzyme and that in both 
cases, GST enzyme had a similar level of function. The first enzyme, promotes the elimination 
of reactive species and the second acts on toxins. Additionaly, Prasad et al. [84], conducted a 
study, which showed that administering GSH to patients with atherosclerosis reduced the risk 
factors and the endothelial injury and, consequently, increased NO concentration and 
antioxidant action.  
Hypertension is a chronic increase of blood pressure. It may result from genetic trait or 
acquired condition and presents different degrees of intensity, such as, mild, moderate and 
severe [85]. Some studies, conducted in animals and humans, suggest that an increased 
concentration of reactive species and oxidative stress are the cause and the consequence, 
respectively, of that condition. The vascular system has antioxidant defense mechanisms, such 
as, SOD, GSH, catalase, Trx and Prx mentioned above, but the failure of these systems in 
synergy with increase of ROS, causes hypertension [86, 87]. It has been observed that the 
GSH:GSSG ratio is superior in whole blood and in EC of hypertensive individuals, and that 
inhibition of GSH pathways induces an increase of blood pressure [87]. 
Diabetes is characterized by elevated glucose levels in the blood, a condition that 
affects physiological metabolism and causes cellular dysfunction. This status represents a 
group of other conditions, such as, hyperglycemia and hyperlipidemia that express the excess 
of free fatty acids and insulin resistance [88]. It induces a set of events, such as, elevated 
oxidative stress, inflammation and platelet hyperactivity, in the vessel wall, causing severe 
dysfunction [19]. Hyperglycemia promotes the production of ROS and RNS by NADPH oxidase 
activation. Additionally, it inhibits the pentose phosphate pathway (PPP) by down-regulation 
of glucose-6-phosphate dehydrogenase enzyme (G6PD). This last route is an important source 
of NADPH, which is also essential in the conversion of oxidized GSSG to the reduced GSH form. 
Therefore, by reducing the PPP flow, levels of glucose are elevated and elimination of NADPH 
contributes to ROS accumulation [89]. Thus, it seems that diabetes is a condition that increases 
the oxidative stress of cells. 
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1.2.2.2. Homocysteine 
 Hcy is a non-protein amino acid, discovered in 1931 by DuVigneaud [90] when he tried 
to get 2Cys by making Met react with sulphuric acid. Hcy is an endogenous thiol that, in 
physiological conditions, is not incorporated into functional or structural proteins [91]. It 
derives from Met and, when it is further catabolized, results in Cys [92]. So, these three amino 
acids are structurally similar. Met has one more methylene group (–CH2) than Hcy and Cys has 
one less –CH2 (Figure 12). These thiols present a sulphur atom in their molecular structure, 
which determines a large reactive capacity. Met has another biochemical feature that stands 
out, the methyl group (-CH3). It provides a high hydrophobic character and is important for 
proteins at structural and fuctional levels [93] (for example in interaction with lipid barriers 
[94]). 
The conversion of Met to Cys is an irreversible reaction, the bioavailability of the latter 
is directly related to dietary habits and the metabolism of Hcy, which will be discussed ahead 
[95]. These three amino acids are important molecules for the normal functioning of living 
organisms, and nutritionally, only Met is considered essential, since it comes from food.  
   
Figure 12 - Representation of the molecular structure of homocysteine, methionine and cysteine. 
 
I. Relevance of cysteine and methionine 
The Cys residue of Hcy is responsible for dimer formation, through disulfide bonds 
between homocysteines, known as homocystine (2Hcy), or with other Cys, called 
cystinylhomocysteine (Cys-SS-Hcy). These oxidation and reduction reactions occur 
spontaneously (Figure 13).  
 
Figure 13 - Redox reaction of homocysteine. Abbreviations: H+ - free hydrogen cation; e- - free electron. 
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At protein level, Cys residues are responsible for forming intra (P1-SS-P1) and inter (P1-
SS-P2) disulphide bonds [96] that ensure structural stability and even protein functionality [94]. 
These chemical bonds also play an important role in the post-transcriptional processing and 
balance between synthesis and degradation of intracellular proteins [97].  
The Cys proteinases are important precursors of other molecules, like endorphin and 
insulin. They have been related to some pathologic processes, like those that originate arthritis, 
muscular dystrophy and tumor metastasis [98].  
Like Cys, Met residues are critical in protein complexes, as their oxidation leads to 
enzyme activation or metabolic signalling [93]. The reaction is represented in figure 14, where 
the Met residue of a protein is oxidized by methionine peroxidase (MPx), through the 
interaction with H2O2. In addition, the reduction reaction, mediated by methionine sulfoxide 
reductase (MSR) is also shown [94]. This is an important path for eliminating some of the 
reactive oxygen species, which are harmful to cell metabolism. However, some studies have 
shown that the increase of methionine sulfoxide residues (Met-R-O) is responsible for vascular 
cell dysfunction, thrombosis, neurodegenerative diseases and a decrease in average life 
expectation [94, 99].  
 
Figure 14 - Redox reaction of the methionine residue in proteins. Abbreviatons: H+, hydrogen cation; 
H2O, water; H2O2, hydrogen peroxide; MPx, methionine peroxidase; MSR, methionine synthase 
reductase; NADP+, nicotinamide adenine dinucleotide phosphate oxidized; NADPH, nicotinamide 
adenine dinucleotide phosphate reduced; Protein-Met, methionine residue in the protein complex; 
Protein-Met-O, protein complex with methionine sulfoxide residue. Adapted from Brosnan et al. [93].   
 
II. Homocysteine metabolism 
Hcy results from the demethylation reaction (Figure 15), consisting in the removal of 
one –CH3 group from Met, which is acquired from diet [100]. This pathway is also called 
methionine metabolism [93]. It involves the catalytic action of methionine S-
adesonyltranferase (MAT), an ATP-dependent enzyme that induces the transfer of the 
adenosyl moiety of ATP to Met. From this reaction, S-adenosylmethionine (SAM or AdoMet) a 
high-energy compound results, due to the sulfuric bond established between the carbon atom 
from the ribose and the sulfur atom of the amino acid. Then, SAM is further converted to S-
adenosylhomocysteine (SAH or AdoHcy) by removal of a –CH3 group [93, 100]. The conversion 
of SAM to SAH is also performed by glycine N-methyltransferase (GNMT) to give sarcosine 
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(Sar), which is subsequently regenerated to Gly in the mitochondria [96]. Following the 
reaction, SAH is hydrolyzed by S-adenosylhomocysteine hydrolase (SAHH) to Hcy and 
adenosine. This hydrolysis is generally irreversible, but in certain physiological conditions, the 
equilibrium may favor SAH synthesis as Ado and Hcy are rapidly removed [100, 101].  
 
Figure 15 - Homocysteine synthesis, also called demethylation of methionine. Abbreviatons: Ado, 
adenosine; ADP, adenosine diphosphate; ATP, adenosine triphosphate; Gly, glycine; GNMT, glycine N-
methyltransferase; H2O, water; Hcy, homocysteine; MAT, methionine S-adenosyltransferase; Met, 
methionine; Pi, inorganic phosphate; R, methyl group acceptor; R-CH3, methylated acceptor; SAH, S-
adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; SAM, S-adenosylmethionine; Sar, 
sarcosine. Adapted from [93, 100]. 
Regulation of this pathway occurs by a negative feedback mechanism of SAH on MAT 
activity, if there is an increase of SAH concentration. However, SAM levels are controlled by 
allosteric interaction when Met levels are high, inactivated MAT returns to the active form by 
interaction with Met [93].  
SAM is a powerful methyl donor in many reactions, involving DNA, RNA, proteins and 
lipids, such that the SAM:SAH ratio allows to estimate the cellular methylation capacity [100]. 
In humans, Hcy metabolism is ubiquitous and the fate of Hcy depends on the tissue 
where it is produced and the cellular metabolic state. After its synthesis, this thiol compound 
may intervene in two pathways, the remethylation or the transsulfuration, with the main role 
of transfering methyl groups [102]. 
The remethylation pathway (figure 16) consists in capturing a methyl group from the 5-
methyltetrahydrofolate (mTHF or 5-MethylTHF), which is converted into tetrahydrofolate (THF) 
and regenerating the amino acid Met [101]. This reaction is catalysed by methionine synthase 
(MS), an enzyme whose activation depends on the cofactor cobalamin, also called vitamin B12 
[103]. It takes place in nearly all cells, with the exception of erythrocytes and hepatocytes 
where the methyl group comes from the reduction of betaine, also named trimethylglycine 
(TMG), catalysed by betaine-homocysteine methyltransferase (BHMT), an enzyme that does 
not require cofactors [100]. The remethylation pathway consists of a step in the folate cycle 
and its relevance is specified ahead. 
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Figure 16 - Remethylation reaction of homocysteine. Abbreviatons: B12, vitamin of complex B; BHMT, 
betaine-homocysteine methyltransferase; DMG, dimethylglycine; Hcy, homocysteine; Met, methionine; 
MS, methionine synthase; mTHF, 5-methyltetrahydrofolate; THF, tetrahydrofolate; TMG, 
trimethylglycine. Adapted from House et al. [101].  
The transssulfuration pathway (figure 17) is an irreversible reaction of cystathionine β-
synthase (CBS), an enzyme dependent on pyridoxal-5'-phosphate (PLP - active form of vitamin 
B6), which binds Hcy to serine (Ser) and forms cystathionine [100]. Thereafter, the latest is 
hydrolyzed by cystathionase γ-liase (CSE), also PLP dependent, cleaving the molecule into Cys, 
α-ketobutyrate and ammonia (-NH4+) [103]. This pathway occurs mainly in the liver, kidney, 
pancreas and small intestine, where the excess of Hcy is adjusted, and is an alternative route 
for Cys synthesis [93, 94]. Moreover, the concentration of Cys is controlled by oxidation to 
taurine, which is eliminated by urinary excretion in the inorganic sulfate form [100], or is 
metabolically directed to gluthatione metabolism, that was discussed above. The regulation of 
this reaction is mediated by SAH, which inhibits CBS enzyme and, by synergic action, of SAM 
that blocks the methylene tetrahydrofolate reductase (MTHFR) from the folate cycle, 
promoting the transsulfuration and secondarily limiting the Hcy remethylation [100, 103]. 
It should be emphasized that the reaction of CSE enzyme produces H2S, a gaseous 
molecule mentioned above, which modulates blood pressure and is crucial in cardiovascular 
homeostasis [104, 105]. 
 
Figure 17 - Transsulfuration reaction of homocysteine metabolism. Abbreviatons: B6, vitamin from B 
complex; CBS, cystathionine β-synthase; Cys, cysteine; Hcy, homocysteine; H2S, hydrogen sulfide, SAH, 
S-adenosylhomocysteine; Ser, serine. Adapted from [100, 103]. 
The reactions of demethylation of Met, the remethylation and the transsulfuration of 
Hcy are all interconnected and form the Hcy metabolism, as shown in figure 18. The pathway is 
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mainly controlled by feedback mechanisms over key enzymes and by regulating the 
concentration of each intermediate [106]. In addition, the diet also has a major contribution, 
since it is the main souce of methionine, an essential amino acid [94]. As mentioned above, 
Hcy metabolism is directly related to bioavailability of methyl groups. Therefore, when the 
organism has deficiencies of these metabolites, cells promote methylation reactions instead of 
catabolism. But, in the opposite situation, there is a decrease of the remethylation pathway 
[93]. 
 
Figure 18 - Homocysteine metabolism. Abbreviations: Ado, adenosine; ADP, adenosine 5'-diphosphate; 
ATP, adenosine 5'-triphosphate; B6 and B12, cofactors derived from B vitamin complex; BHMT, betaine-
homocysteine methyltransferase; CBS, cystathionine β-synthase; Cys, cysteine; DMG, dimethylglycine; 
Gly, glycine; GNMT, glycine N-methyltransferase; H2O, water; Hcy, homocysteine; MAT, methionine S-
adenosyltransferase; Met, methionine; MS, methionine synthase; mTHF, 5-methyltetrahydrofolate; Pi, 
inorganic phosphate; R, methyl group acceptor; R-CH3, acceptor methylated; SAH, S-
adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; SAM, S-adenosilmethionine; Sar, 
sarcosine; Ser, serine; THF, tetrahydrofolate; TMG, trimethylglycine. Adapted from [100, 106]. 
 
III. Homocysteine and the folate cycle 
As seen above, Hcy is involved in another metabolic pathway, critical for all types of 
cells, the folate cycle, which is illustrated in figure 19. This cycle consists on the catalytic 
transfer of carbon units through derivatives of folic acid, also called folate or vitamin B9 [100]. 
The cycle begins when this compound is available in the cells, where it is recognized by 
Quantification of Oxidative Stress Biomarkers: Development of a Method by Ultra Performance Liquid 
Chromatography 
July 2016 
 
23 
 
dihydrofolate reductase (DHFR), the enzyme that converts it into THF, by transfering one 
carbon atom. Subsequently, THF accepts one carbon from Ser amino acid, being transformed 
into 5,10-methylenetetrahydrofolate (meTHF), mediated by serine hydroxymethyltransferase 
(SHMT) a vitamin B6-dependent enzyme [91]. Then, meTHF suffers reduction by MTHFR, which 
requires FAD, the active form of vitamin B2, and becomes mTHF [93]. At this point, Hcy the 
intermediate from the remethylation pathway that receives a methyl group from mTHF, arises. 
This reaction is catalysed by MS coupled to vitamin B12 [94]. Thus, THF and Met are 
regenerated, available to initiate a new cycle or metabolically directed. SAM regulates this 
cycle by inhibition of MTHFR. Therefore, when SAM concentration is low, mTHF synthesis 
occurs and the transsulfuration pathway is inhibited, which enhances the conversion of Hcy to 
Met. Oppositely, when SAM levels are elevated, Hcy is converted into Cys and the folate cycle 
is suppressed [100]. 
 
Figure 19 - Schematic representation of the folate cycle. Abbreviatons: B2, B6 and B12, cofactors derived 
from B vitamin complex; DHFR, dihydrofolate reductase; FAD, flavine adenine dinucleotide oxidized; 
FADH2, flavin adenine dinucleotide reduced; Gly, glycine; H+, hydrogen cation; Hcy, homocysteine; Met, 
methionine; meTHF, 5,10-methylenetetrahydrofolate; MS, methionine sintetase; mTHF, 5-
methyltetrahydrofolate; MTHFR, methyltetrahydrofolate reductase; NADP+, nicotinamide adenine 
dinucleotide phosphate oxidized; NADPH, nicotinamide adenine dinucleotide phosphate reduced; Ser, 
serine; SHMT, serine hydroxymethyltransferase; THF, tetrahydrofolate. Adapted from [89, 100]. 
 
IV. Relevance of vitamins  
Vitamins are essential in Hcy metabolism, because they mediate the activation of 
almost all the intervening enzymes. Among them, there are several cofactors derived from B 
complex vitamins. PLP, the active form of vitamin B6, interacts with CBS, γ-cystathionine and 
SHMT; FAD, derived from B2, is connected to MTHFR and MS; Methylated B12 activates MS; and 
B9 is one of the main cofactors in Hcy metabolism [100]. B vitamin deficiencies are associated 
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with an increase in Hcy plasma levels and with the emergence of pathological conditions 
caused by hyperhomocysteinemia (HHcy). On the other hand, vitamin bioavailability is directly 
related to diet and lack of these molecules is related to the development of some metabolic 
abnormalities [94]. 
HHcy is an established independent risk factor for vascular disease [107]. Therefore, 
the scientific community has been investigating the possibility of prevention and treatment of 
cardiovascular diseases (CVD) with oral administration of B vitamins. However, the studies of 
therapy supplementation with these molecules, in patients with CVD, have been a matter of 
great controversy, since results were not as expected. A couple of studies demonstrated that 
taking a supplement mixture of B vitamins (B9, B6 and B12), successfully reduced plasma Hcy 
concentration. However, also showed that the risk for development vascular disease was not 
reduced [108, 109]. In another study, subjects who had previously suffered from myocardial 
infarction were followed and B vitamins did not decrease the prevalence or the possibility of 
new disease events. Although the concentration of Hcy was lower, the condition prevailed and 
the risk of health complications or even death, due to vascular abnormalities, was a reality 
[110]. Further studies have been inconclusive. They found no effective or significant 
relationship of cause and effect between vitamin supplementation and prevention of CVD [111, 
112]. Anyway, these scientific studies have been important because they have demonstrated 
that CVD are multifactorial and that it is necessary to know more about them to find ways of 
prevention and treatment, which can be specific and effective. 
 
V. Homocysteine levels 
 Hcy levels in humans are determined by physiological and genetic factors, as well as, 
nutritional elements and lifestyle. Sometimes the term “total homocysteine” is used in the 
wrong sense, since studies did not include a number of related molecules. Usually, total Hcy 
(tHcy) includes the free or reduced form, the oxidized forms and the ones that are linked to 
protein complexes. Apart from these, there are Hcy-thiolactones, SAH, homocysteic acid, 
homocysteine sulfinic acid, cystathionine, among others, which are not accounted as total Hcy 
[113]. In humans, it is considered that approximately 80% of this compound is coupled to 
proteins, such as, albumin and hemoglobin [96]. Nearly 19% is in the disulphide form and only 
1% is free [113]. Either way, the normal concentration in human blood is considered to be in 
the range of 5 to 15 µM [101]. In cell cultures there is no specific range, because the 
concentration may vary more sharply, as it depends on the cell type and the method used. 
Moreover, under pathological conditions plasma and urinary levels become higher, a 
disorder called HHcy and homocysteinuria, respectively [114]. In the most severe cases of 
homocysteinuria, the abnormal accumulation of Hcy can reach up to 500 µM [115]. HHcy cases 
are classified in tree cathegories, according to Hcy concentrations [114]: i) weak or mild (15 to 
24 µM); ii) intermediate or moderate (25 to 100 µM); and iii) severe (above 100 µM). 
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VI. Homocysteine and pathological relationship  
 Hcy, as a risk factor for CVD, causes endothelial injury, vascular smooth muscle 
proliferation, high-density lipoprotein (HDL) cholesterol inhibition, thrombogenesis and 
autoimmune responses [114]. The increase of concentration alters the hemodynamic 
properties of the cardiovascular system, emphasizing a decreased NO bioavailability, by an up-
regulation of endogenous asymmetric dimethylargenine (ADMA). The latest is an endogenous 
inhibitor of the endothelial nitric oxide synthase (eNOS) [116]. All these conduct to an 
induction of endothelial dysfunction. Also, as noted above, elevated levels of Hcy increase the 
concentration of reactive species and these, in turn, increase the production of oxidant 
molecules, such as, thiolactones that will be specified later, which damage the endothelium. 
Therefore, Hcy mediates metabolic disregulation by expression of pro-coagulant, pro-
thrombotic and pro-inflammatory responses.  
Several mechanisms have been proposed to try to explain Hcy associated pathologies. 
Metabolic disorders mediated by Hcy arise mainly from genetic abnormalities and vitamin 
deficiencies, which affect metabolic proteins, such as, CBS, MTHFR and MS. For example, a 
mutation in the MTHFR gene is associated with vascular disease, colon cancer, leukemia and 
impairment of neural tube formation [117]. Sultan et al. [118], reported a study where it was 
demonstrated that different MTHFR gene mutations resulted in different HHcy categories. 
Hence, plasma Hcy concentration is also dependent on the MTHFR genotype. The same may 
occur with any type of mutation in genes encoding enzymes of Hcy metabolic pathway. 
In HHcy, the most important issues are the regulation of Hcy production and transport, 
within cells and between different tissues. In 2007, Jiang et al. [119] studied Hcy transport 
mechanisms in EC and vascular smooth muscle cells (VSMC), which occured through four 
systems called XAG, ASC, A (Na+ dependent) and L (Na+ independent). They found that EC hold 
Hcy intracellular levels in high levels and against plasma concentration gradient. It was proved 
that Hcy transport is inhibited in basic medium and that it is highly dependent on an intact 
lysosomal system, since it has inhibitory molecules [119]. They also demonstrated that the 
excess of Hcy uptake by cells is not the cause of endothelial damage. They claim that the injury 
induced by Hcy cannot be attributed to an increase of absorption, it must be other biochemical 
mechanism, independent of Hcy absorption, which is responsible for the cytotoxic effects 
[119]. 
HHcy causes an increase of ROS production directly or through auto-oxidation 
pathways, such as, decreased action of antioxidant systems (GSH and superoxide dismutase) 
or increase of NADPH oxidase, respectively [73]. There is some evidence that subjects with 
sclerosis or amyotrophic lateral sclerosis (ALS), conditions that are characterized by decreased 
nerve and muscle functions or degeneration, have high plasma levels of Hcy. Some studies 
have shown that HHcy causes muscle cell metabolic abnormalities, due to increased 
production of creatinine phosphokinase (CPK), the enzyme that controls the energy potential 
[120]. All the above-mentioned conditions induce endothelium oxidative stress and injury, 
which affects the cardiovascular system, kidneys, brain or muscles and, consequently, can lead 
to multiple organ failure [121].  
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HHcy and hypercholesterolemia are considered independent risk factors in the 
emergence of CVD. Some studies have shown a positive correlation between Hcy and 
cholesterol, such as, the increase of one directly influences the increase of the other [122]. 
Therefore, the degree of endothelial dysfunction in HHcy is considered to be similar to that of 
hypercholesterolemia and hypertension conditions [123]. 
Some metabolic abnomalies result from Hcy thiolactones formation, due to errors of 
aminoacyl-tRNA synthetase, the enzyme that carries out esterification of amino acids in RNA 
transfer (tRNA) to form aminoacyl-tRNA, in protein transcription processes [124]. When Hcy 
concentration is high, some metabolic abnormalities emerge and affect the methylation 
process of Hcy-tRNA to Met-tRNA, due to the reduction of transmethylation or 
transsulfuration pathways [91]. As a result, formation of a cyclic thioester occurs, by the action 
of methyonyl-tRNA synthetase (MetRS), an ATP-dependent enzyme, that condenses the thiol 
group with the carboxylic acid, as shown in figure 20. This reaction was first described in 
Escherichia Coli bacteria [125] and was later identified in several eukaryotic cells, such as, 
fibroblasts, endothelial, hepatic and in breast cancer cells [91].  
 
Figure 20 - Reaction of homocysteine thiolactones formation. Abbreviatons: AMP, adenosine 5'-
monophosphate; ATP, adenosine 5'-triphosphate; Hcy, homocysteine; MetRS, methionyl-tRNA 
synthetase; MetRS·Hcy-AMP, methyonyl-tRNA bound to homocysteine adenylate; PPi, inorganic 
pyrophosphate; tRNA, transfer ribonucleic acid. Adapted from Medina et al [91]. 
Thiolactones induce protein homocysteinylation by reacting with the amino group (-
NH2) of lysine residues, causing changes in the physical and chemical properties of the 
modified protein. The injury caused by this reaction is one of the conditions that lead to 
vascular endothelium damage and development of atherosclerosis [125]. Cells have a 
protection mechanism, which eliminates these reactive compounds and prevents 
homocysteinylation. It is mediated by an Hcy-thiolactonase hepatic enzyme also called 
paraoxonase, which is calcium and HDL dependent. Paraoxonase hydrolyzes thiolactones back 
to Hcy [124].   
This way, Hcy is also considered a risk factor of hypertension, systolic and diastolic 
blood pressure (SBP/DBP) greater than 140/90 mmHg [85]. However, there is no consensus, or 
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an exact explanation for this relationship because the results of several studies were 
ambiguous [126]. Wang et al [127], investigated the relationship between plasma Hcy 
concentration and the incidence of hypertension. Like in other studies [128], they showed that 
men with high levels of Hcy had an increasead risk, but the data were not statistically 
significant in the incidence of hypertension. Furthermore, the results suggested that in an early 
stage of hypertension, lower Hcy levels might indicate higher risk. Thus, it is considered that 
HHcy cannot simply be related to the increased risk of incidence. Moreover, the levels of Hcy 
in women are lower and compared with these values, a significant risk factor was not observed 
[127, 128]. Therefore, we can say that the causal relationship of Hcy concentration and 
hypertension is not simple or absolute.  
HHcy has been related to the antiphospholipid antibody syndrome (APS), also known 
as Hughes syndrome, which is characterized by the formation of blood clots due to 
autoimmune reactions [129]. However, the studies presented did not find a significant 
relationship between clinical manifestations and this pathological condition [130].  
 
To summarize, Hcy plasma levels greater than 15 µM are considered to be pathologic. 
The increase may arise from disruptions of metabolic pathways due to nutritional deficiencies, 
enzymatic or genetic abnormalities, which further cause oxidative stress and damage in the 
vascular endothelium. 
Since the late 60´s, Hcy plasma levels have been associated with CVD, especially in the 
emergence of atherosclerosis [131]. In 1962, McCully [132] reported the first cases of severe 
homocysteinuria in children with mental retardation, accelerated growth, osteoporosis, 
arterial thrombosis and atherosclerotic plaque. One child showed CBS deficiency so, did not 
synthesize cystathionine and evidenced high levels of Hcy and Met in plasma. Another child, 
who lacked MS enzyme, presented high plasma cystathionine and Hcy concentrations and low 
levels of Met [92]. Since then, a high concentration of Hcy was directly associated to the 
induction of atherosclerosis 
Atherosclerosis describes a slowly progressive disease (Figure 21), which results from 
continuous inflammatory damage that increases the vascular permeability, induces fat 
accumulation and formation of atherosclerotic plaque in arterial walls [133]. Furthermore, this 
process can occur in veins subjected to arterial pressure and in the pulmonary system, in 
hypertension conditions [134]. Morphologically, arteries have a trilaminate structure 
composed of tunica adventitia of connective tissue, tunica media of smooth muscle, elastic 
tissue and collagen, and the intima tunic of endothelial tissue [135]. This pathological condition 
begins at the endothelial layer, with a series of hemodynamic changes, which subsequently, 
transmit molecular signals that activate several reactions throughout the vascular system, such 
as, cells recruitment, production of inflammatory molecules and lipid accumulation [17, 135]. 
In the EC, the chemical damage caused by Hcy is considered to be one of the earliest reactions 
that occur in the development of atherosclerosis [136].  
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Figure 21 - Development and progression of atherosclerosis. Legend: (a) normal artery, a trilaminate 
structure; (b) early atheroma emergence due to endothelial dysfunction and inflammatory reaction; (c) 
growth of lipid plaque through a pro-inflamatory cascade; (d) rupture of the atherosclerotic plaque; (e) 
thrombus formation; (f) lipid-lowering, reduction of lipid content and control of the inflammatory 
response; (g) healing response may stimulate tissue proliferation and constrict the lumen. Image and 
information adapted from [136, 138].  
Endothelial activation in atherosclerosis, as shown in figure 22, mediates the 
production of cytokines and the expression of molecular markers at the surface of EC, which 
cause adhesion and migration of monocytes. Increase of the endothelial permeability allows 
LDL-cholesterol to cross the vessel wall and, consequently, monocytes differentiate into 
macrophages that capture oxidized LDL-cholesterol and become foam cells (Macrophages 
loaded with fat) [139]. The pro-inflammatory cytokines promote more cell recruitment, 
smooth muscle proliferation and vascularization that lead to localized thickening of the vessel 
becoming an atherosclerotic plaque. Thus, as the plate increases, narrowing of the lumen and 
blood deprivation occur [140]. In certain cases, the weak vessel can leak blood, causing intra-
plaque hemorrhage, which may accelerate the injury. Hypoxia and oxidative stress leads to 
apoptosis of the foam cells and the formation of a necrotic lipid cluster [141]. The 
inflammatory condition prevails when the risk factors are elevated, such as, in case of 
dyslipidemia and HHcy. Moreover, hypertension promotes this condition through multiple 
mechanisms and interaction with other risk factors, such as, poor diet and smoking [142].  
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Figure 22 - Development of atherosclerotic plaque, highlighting the endothelial activation pathway and 
oxidative modifications that precede endothelial injury. Abbreviatons: LDL, low-density lipoprotein; RS, 
reactive species. Legend: Oxidized LDL-cholesterol stimulates chemotaxis (A), prevents the exit of 
monocytes from the subendothelial space (B) and mediates the formation of foam cells (C), which 
subsequently, become necrotic due to accumulation of oxidized LDL-cholesterol (E). As a final result, 
endothelial dysfunction emerges (D). Adapted from [139, 140].  
Hypertension and atherosclerosis are pathologically linked. The NO molecule is an 
endothelial mediator of the inflammatory signal, which produces vascular relaxation and 
expression of specific factors that control oxidative stress, leukocytes adhesion and pro-
thrombotic reactions [17]. In the case of chronic hypertension, it alters the homeostatic 
mechanisms expressing an early inflammatory response and formation of atherosclerotic 
plaque. Thus, hypertension, over the matrix vessel wall is associated with an increase of 
proteoglycans and a production of ROS of pro-inflammatory action, like O2- and HOCl [140]. 
The interaction of these particles increases the oxidation susceptibility of LDL-cholesterol and 
subsequent uptake by macrophages. In addition, the friction exerted on the vessel wall due to 
blood circulation, also stimulates the increased production of NO [142]. In atherosclerosis 
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condition, the presence of homocystine thiolactones promotes the formation of foam cells and 
accelerates the pathological condition state. Effectively, homocysteinilated LDL-cholesterol is 
more susceptible to oxidation than native LDL-cholesterol because it is more easily recognized 
and captured by macrophages [125]. Tsen et al. [143], found that in humam umbilical vein 
endothelial cells (HUVEC), Hcy inhibits ROS production and NO accumulation within the first 
hours of exposure (0.5 h), in a concentration from 0.25 to 1 mM. However, when the 
treatment was extended for longer than 22 to 24 hours, ROS synthesis was stimulated and NO 
was eliminated. They considered that endothelial dysfunction resulted from increased ROS 
over NO concentrations. They also showed that 5 mM of Hcy has cytotoxic effects in cells. On 
the contrary, Cys, which is a GSH precursor, has a protective effect and reduces ROS 
production in the initial state or after chronic exposure of Hcy, even exceeding 1 mM. Studies 
with Met were also performed but no significant effects were found [143]. Thereby, this work 
confirmed that Hcy limited NO bioavailability in HUVEC cells, directing metabolism to the 
formation of reactive compounds that cause oxidative stress and induce endothelial 
dysfunction. 
 In another study, an electrochemical detection of Hcy concentration was carried out in 
rat microvascular endothelial cells (RMVEC) [144]. Hcy was found to have an indirect action 
over NO production. Hcy caused suppression of NO production in cell culture in vivo, 
stimulating several eNOS dependent and independent receptors. They proved that Hcy 
oxidized eNOS sulfhydryl groups, inhibiting its activity [144].  
Additionally, Li et al. [145] assessed gene expression in HHcy conditions, using cDNA 
microarrays, in HUVEC cells and found that there is an increase of the messenger RNA 
transcript, which expresses 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) intervening in 
cholesterol biosynthesis. They proved that Hcy increases cholesterol production and 
accumulation in EC. Control cultures showed that free cholesterol is accumulated in the 
endoplasmic reticulum and plasma membrane. However, HUVEC cell cultures in HHcy 
conditions evidenced lipid droplets throughout the cytoplasm, a condition observed in the 
formation of foam cells [145]. 
 
The relationship between Hcy, ADMA and NO, in HUVEC cell cultures, has also been 
studied and Hcy was found to induce synthesis and accumulation of NO and ADMA [146]. 
Other studies showed that Hcy blocks the enzymatic activity of dimethylarginine 
dimethylamine hydrolase (ADHD) with accumulation of ADMA and ROS, which are inhibitors of 
NO sysnthesis [116]. Tan et al. [147], demonstrated that HHcy stimulates the proliferation of 
VSMC, altering the structure of the vascular matrix through the production of collagen fibers. 
Consequently, it diminishes the elasticity of the vessel and leads to arterial remodeling and 
increased vascular resistance [147]. 
Although, many scientific research studies have been conducted, the mechanisms of 
pathologic action of thiol compounds in vascular homeostasis remain unknown.  
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1.2.3. Purines  
Purines constitute a group of molecules, which are closely related to the previously 
mentioned thiol compounds. They are nitrogenous bases that bind to a pentose and one or 
more phosphate groups, forming nucleotides (Figure 23) [148]. Nucleotides are the 
monomeric units of nucleic acids, but they also play important functions in the cells, 
particularly as energy storage, cellular messengers and also act as enzyme cofactors. All 
nucleotides contain one type of sugar, the pentose ribose (RNA) or a deoxyribose (DNA). There 
are also two types of bases (heterocyclic amine) the purines with two ring in its structure and 
the pyrimidines with only one ring, the latest will not be discussed. Thus, nucleotides having 
purine bases are mainly, adenine, guanine and their derivatives [149].  
Purines are precursors of DNA, RNA, coenzymes NAD+, NADP+, FAD and CoA, and of 
several metabolic derivatives as SAM and SAH referred to, above. They are substrates of some 
enzymes, such as, DNA and RNA polymerases and act as signal second messengers, like cyclic 
nucleotides adenosine monophosphate (cAMP) and guanosine monophosphate (cGMP) [150]. 
 
 Figure 23 - Representation of the nucleoside and nucleotide structure. Image obtained from [151]. 
 
1.2.3.1. Purines metabolism 
The purines and pyrimidines are ubiquitous in organisms. The purine metabolism can 
occur by two distinct pathways: “de novo”, a synthetic route for nucleotides, where energy is 
required and the “salvage” pathway, an energy saving mechanism of degradation and 
molecular recycling [150]. 
Purine “de novo” synthesis, also known as IMP pathway, is a set of reactions with the 
final goal of obtaining inosine 5'monophosphate (IMP), through a series of phosphoribosyl 
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pyrophosphate (PRPP) conversions [152]. PRPP is a precursor, which is common to the 
synthesis of purines and pyrimidines, and ribose-5-phosphate is another one. The latest, is the 
first compound in purine biosynthesis, which derives from the PPP pathway. It is the 
intermediate of PRPP and is activated by the enzyme phosphoribosyl pyrophosphate 
synthetase (PRPPS), through ATP consumption with AMP release (Figure 24). In the cells, when 
the concentration of PRPP is low, there is an increase of the “salvage” route, but when the 
concentration is high, there is activation of the “de novo” pathway [150]. 
 
 Figure 24 - Synthesis of phosphoribosyl pyrophosphate (PRPP). Abbreviations: AMP, adenosine 
5'monophosphate; ATP, adenosine 5'triphosphate. Adapted from Moran et al. [153]. 
The complete pathway of purine “de novo” synthesis is represented in figure 25 [152] 
The first reaction is mediated by phosphoribosyl pyrophosphate amidotransferase (PPAT①) 
that displaces the pyrophosphoryl group of PRPP by the amine nitrogen of glutamine (Gln) 
[150]. The product phosphoribosylamine is then acylated by Gly to form glycinamide 
ribonucleotide by action of glycinamide ribonucleotide synthetase (GARS②), an ATP-
dependent enzyme. Then, glycinamide ribonucleotide transformylase (GART③) performs the 
transfer of a formyl group from 10-formyltetrahydrofolate to the N-7 amino group of IMP 
[152]. Subsequently, formylglycinamidine ribonucleotide synthase (FGAMS④), another ATP-
dependent enzyme, converts formylglycinamide-ribotide into formylglycine-amidinoribotide 
and Gln is the nitrogen donor [153]. The next reaction is a ring-closure step where 
aminoimidazole ribonucleotide synthetase (AIRS⑤), which also requires energy in ATP form, 
produces aminoimidazole-ribotide. Then, a carboxylation reaction (CO2 incorporation) is 
performed by aminoimidazole ribonucleotide carboxylase (AIRC⑥) enzyme, requesting ATP 
and HCO2- anion as donor [152]. Following, aminoribosyl-aminoimidazole succinocarboxamide 
ribonucleotide synthetase (SAICARS⑦) incorporates an amine group from the amino acid 
aspartate (Asp) into the precursor and later, the enzyme adenylosuccinate lyase (ADSL⑧) 
reacts and releases fumarate. The following reaction is similar to GART③ action, but it is 
carried out by the aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT⑨).  
Finally, IMP cyclohydrolase (IMPCH⑩) completes this sequence of metabolic reactions and IMP 
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is formed [152, 153]. In this metabolic pathway, there is the intervention of other enzyme, the 
aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate 
cyclohydrolase (ATIC) that also catalyzes the reactions mediated by AICARFT⑨ and IMPCH⑩ 
[154]. IMP is the main precursor of the purines adenine and guanine. 
 
Figure 25 - Schematic representation of purine “de novo” synthesis pathway. Abbreviations:  10-CHO-
THF, 10-formyl-tetrahydrofolate; ADP, adenosine 5'diphosphate; AMP, adenosine 5'monophosphate; 
Asp, aspartate; ATIC, aminoimidazole carboxamide ribonucleotide transformylase/inosine 
monophosphate cyclohydrolase; ATP, adenosine 5'triphosphate; Gln, glutamine; Glu, glutamic acid; Gly, 
glycine; H2O, water; HCO2-, hydrogen carbonate anion; Pi, inorganic phosphate; PPi, inorganic 
pyrophosphate; THF, tetrahydrofolate; Legend: PPAT①, phosphoribosyl pyrophosphate 
amidotransferase; GARS②, glycinamide ribonucleotide synthetase; GART③, glycinamide ribonucleotide 
transformylase; FGAMS④, formylglycinamidine ribonucleotide synthase; AIRS⑤, aminoimidazole 
ribonucleotide synthetase; AIRC⑥, aminoimidazole ribonucleotide carboxylase; SAICARS⑦, 
aminoribosyl-aminoimidazole succinocarboxamide ribonucleotide synthetase; ADSL⑧, adenylosuccinate  
lyase; AICARFT⑨, aminoimidazole carboxamide ribonucleotide formyltransferase; IMPCH⑩, IMP 
cyclohydrolase. Adapted from Adam [152]. 
When sinthesyzed, IMP may subsequently lead to AMP or GMP, as presented in figure 
26 [153]. IMP has a hypoxanthine base (or hydroxyl group) that in AMP synthesis suffers 
substitution by an amino group through the action of adenylosuccinate synthetase (ADSS) and 
ADLS, consuming aspartate and releasing fumarate. Afterwards, GMP results from oxidation of 
one IMP carbon atom, with reduction of NAD+ by the enzyme IMP hydrogenase, forming 
xanthosine monophosphate (XMP). The latest suffers amination by a GMP syntethase with Gln 
intervention and is converted into glutamate [153]. 
 It is important to note that, in AMP synthesis there is consumption of energy in GTP 
form, and in GMP synthesis there is an intake of ATP form [148]. That is, this is a way of 
energetic adjustment in cells. 
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Figure 26 - Inosine monophosphate conversion. Abbreviations: AMP, adenosine 5'monophosphate; ATP, 
adenosine 5'triphosphate; GDP, guanosine diphosphate; GMP, guanosine monophosphate; GTP, 
guanosine triphosphate; H+, hydrogen cation; H2O, water; IMP, inosine 5'monophosphate; NAD+, 
nicotinamide adenine dinucleotide oxidized; NADH, nicotinamide adenine dinucleotide reduced; Pi, 
inorganic phosphate; PPi, inorganic pyrophosphate. Adapted from Moran et al. [153]. 
Purine synthesis is regulated by complex mechanisms of feedback inhibition as shown 
in figure 27. PPAT enzyme is allosterically inhibited by high concentrations of IMP, AMP or 
GMP products. ADSL enzyme also catalyzes the conversion of IMP to AMP [153]. In transport 
mechanisms, aminoimidazolecarboxamide dephosphorylated ribonucleoside (AICAR) 
competes with Ado, which results in Ado accumulation in the extracellular space due to 
inhibition of A1 receptor [152], receptor specified later on. Following, AICA riboside acts on 
AMP-activated protein kinase (AMP kinase), which is activated by glycogen phosphorylase 
[153]. The AICA ribose, also accelerates the replication of purine nucleotide pools in the heart, 
which consequently increase glucose uptake, gluconeogenesis, and inhibit fatty acids and 
sterol synthesis in hepatocytes [152].  
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Figure 27 - Regulatory mechanisms in purine metabolism. Abbreviations: AMP, adenosine 
5'monophosphate; GMP, guanosine 5’monophosphate; IMP, inosine 5'monophosphate; PRPP, 
phosphoribosyl pyrophosphate; XMP, xanthosine monophosphate. Adapted from Moran et al. [153]. 
 The “salvage” pathways are a form of biochemical recycling. Nucleic acids are 
degraded by nonspecific nucleases, giving rise to polynucleotides, which are subsequently 
converted to nucleotide compounds by the action of phosphodiesterases or exonucleases. 
Nucleotide compounds are hydrolyzed by nucleosidases or nucleoside phosphorylases 
becoming nucleosides and inorganic phosphorus. In purine degradation, two functionally 
related key enzymes stand out: adenosine phosphoribosyl transferase (APRT), which catalyzes 
the reaction between adenine and PRPP to form AMP, and hypoxanthine-guanine 
phosphoribosyltranferase (HGPRT), which acts primarily in the recycling of DNA and RNA [153]. 
In addition, HGPRT catalyzes the reaction between guanine and PRPP to form GMP. 
 Figure 28 illustrates the systhesis of purines focusing on the relevant compounds in 
this study: adenosine and inosine. 
 
Figure 28 - Schematic representation of the metabolic conversions of purine compounds, emphasizing 
those who were determined in this study. Adapted from Moran  et al. [153]. 
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1.2.3.2. Adenosine and Inosine 
Ado is a nucleoside belonging to the purine family first described by Drury and Szent-
Györgyi  in 1929 [155], as an important signaling molecule that is present in the extracellular 
space. It is widely distributed throughout the body, in the nervous, immune, cardiac, 
gastrointestinal, renal and in muscle systems. Under normal conditions, Ado cytoplasm 
concentration is around 0.01 to 0.10 µM and in the interstitial fluid it varies between 0.02 and 
0.2 µM [156]. This nucleoside is a hydrophilic compound, so, its transport through the 
membrane is mediated by proteins [157]. It has protective and neuromodulating properties, 
which trigger physiological responses by interacting with specific receptors. It is a molecule of 
great importance at the scientific level, because of its high therapeutic potential [158]. 
Ino is another purine nucleoside, an Ado related metabolic compound in the pathways 
of synthesis and degradation. The deamination of Ado forms Ino through a reaction catalyzed 
by adenosine deaminase (ADA) [159]. As presented in figure 29, structurally, Ino has a nitrogen 
less and one more oxygen atom, than Ado. Functionally, Ino is also a relevant 
immunomodulator and neuroprotective compound [160]. Just as Ado in human plasma, Ino 
derives from dietary and endogenous purine metabolism. 
  
Figure 29 - Representation of the molecular structure of adenosine and inosine. 
 
I. Adenosine specific pathway 
As shown in figure 30, Ado results from the catabolism of ATP to ADP, and then to 
AMP, which subsequently regenerates Ado molecule by the action of endo and ecto-5-
nucleotidase. In the cytoplasm, demethylation of Met in Hcy remethylation pathway is another 
source of Ado [161]. Reviewing the latest pathway, it involves the catalytic action of MAT with 
formation of SAM, which is then hydrolyzed to SAH that thereafter, originates Hcy and Ado. 
Subsequently, the nucleotide can be rephosphorilated to AMP by adenosine kinase (ADK), or 
catalyzed by ADA, giving Ino [157]. 
cAMP is a second messenger produced from AMP, by adenylyl cyclase (AC) activation, 
and it is dependent upon the action of other proteins that affect its synthesis and degradation 
[162]. Its fundamental role in cells is related to signal response of some hormones and 
neurotransmitters, for example in the activation of protein kinase A (PKA), a phosphorylating 
enzyme [163]. ATP, ADP, Ado and cAMP, when needed, are exported from cells, through 
diffusion or active transport (TX). Thus, anabolism and catabolism rate of ATP mediated by Ado 
is a pathway responsible for maintaining the normal energetic state of the cells. The 
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intracellular signaling cascade, mediated by Ado is a complex process, regulated at 
transcriptional level [164]. Ado transport to the intracellular space is made through specific 
transporters, named equilibrative nucleoside transporter 1 and 2 (ENT1 and ENT2), where it is 
transformed to Ino or AMP by the action of ADA or ADK, respectively [158].  
 
Figure 30 - Adenosine metabolism. Abbreviatons: 5'NT, 5'-nucleotidase; AC, adenylyl cyclase; ADA, 
adenosine deaminase; ADK, adenosine kinase; Ado, adenosine; ADP, adenosine diphosphate; AK, 
adenylate kinase; AMPD, adenosine monophosphate deaminase; ATP, adenosine triphosphate; cAMP, 
cyclic adenosine 3'5'-monophosphate; Hcy, homocysteine; IMP, inosine monophosphate; INK, inosine 
kinase; Ino, inosine; Met, methionine; PDE, phosphodiesterase; R-CH3, methylated acceptor; SAH, S-
adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; SAM, S-adenosylmethionine; TX, 
protein carrier. Legend: 1, ecto-ATPases; 2, ecto-phosphodiesterase (Ecto-PDE); 3, ecto-5'-nucleotidase 
(Ecto-5'NT); 4, adenosine receptors A1, A2A, A2B or A3. Adapted from [165, 166]. 
As mentioned above, Ino is an important metabolic intermediate in Ado synthesis, but 
also, it has a crucial intervention in RNA editing. This mechanism is responsible for RNA and 
protein diversity, independently from the genetic code [167]. Ino is a modified nucleotide base, 
which derives from the reaction of ADA enzyme over RNA chain converting Ado into Ino. It is 
considered a rare base that usually, is not a part of RNA. However, it is common in tRNA [167], 
interference RNA (RNAi) [168] and micro RNA (miRNA) [169]. These modifications are 
responsible for variations in the genetic sequences encoding proteins, which may compromise 
their functional properties [167], as, for example, in cardiovascular system [170].  
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II. Specific functions of adenosine and pathological relationship 
The functions mediated by Ado begin with interactions with the adenosine receptors, 
which in turn, modulate cell signaling. There are four receptor subtypes, A1, A2A, A2B and A3 (or 
A1R, A2AR, A2BR and A3R [175] as represented in figure 31), which are highly specific, belong to 
the heteromeric G proteins signaling family and are composed by seven transmembrane 
domains (Heptahelical receptor) with an extracellular amine terminus and a cytoplasmic 
carboxy terminus [171]. Extracellular Ado interacts with the G-protein complex and produces a 
response that can be activation (A2A and A2B) or inhibition (A1 and A3) regarding the AC enzyme 
activity, as illustrated in figures 30 [166]. This specificity is important in therapeutic applications, 
such as, at anti-inflammatory (A2A and A3), cardiac (A1, A2B and A3) [172] neural (A1 and A3) 
levels, and control of pain/stress transmission (A1) [164]. Some of the important actions 
mediated by each specific receptor are:  
- A1 stimulates the action of AC and phospholipase C (PLC) enzymes [156]. It has a 
negative chronotropic (heart rate) and dromotropic effect (stimulus conduction) 
on cardiac tissue and causes vasoconstriction [161]. Some studies, suggest the use 
of an antagonist of these receptors as a protective agent in the treatment of 
arrhythmias, atrial fibrillation [156] and supraventricular tachycardia [158];  
- A2A and A2B stimulate AC, which increases the levels of cAMP [156]; 
- The activation of A2A in EC, coronary smooth muscle, monocytes and macrophages 
induces vasodilatation, neo-angiogenesis and inhibit the production of pro-
inflammatory cytokines, by acting on neutrophils and lymphocytes in inflammatory 
responses [173]. Binding to Ado, activates the pathway that increases cAMP 
production. It is associated with the activation of PKA, which in turn is able to 
inhibit nuclear factor (NF-kβ) thereby promoting anti-inflammatory activity [174]; 
- Receptor A2B controls the degree of contraction of the vascular system through 
vascular tone [161], vasodilatation, decrease in heart ischemia and reperfusion 
[158]. Also, prevents cardiac remodeling after myocardial infarction and has a 
protective effect on ischemic post-conditioning [156]. As to anti-inflammatory 
response, it stimulates the secretion of cytokines or interleukin, a family of 
compounds also called human cytokine synthesis inhibitory factor (CSIF), such as, 
IL-10. The latest is produced by macrophages, and has anti-inflammatory 
properties [175];  
- A3 stimulates PLC enzyme, which increases calcium levels, modulates the activity of 
protein kinase C (PKC) [166] and chemotactic mechanisms [173]. It inhibits AC, 
decreasing available cAMP, also inhibiting the activity of PKA. Additionally, A3 
induces cardioprotection mechanisms in ischemia heart disease, through 
activation of PKC and regulation of mitochondrial ATP channels [164]. 
The immune capacity is one of the most important functions in our body and it is 
mediated and regulated by Ado release and respective binding to its specific receptors. This 
purine nucleoside regulates innate immunological reactions caused by microorganism 
invasions or tissue damage and reduces the inflammatory response that is triggered [175]. The 
extracellular Ado is a modulator of immunity, by linking to its receptors at the surface of some 
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immune cells, such as, macrophages, lymphocytes, neutrophils [173], dendritic and mast cells. 
Subsequently, as shown in figure 31 [175], each cell type is activated and sets off a particular 
mechanism and specific responses. For example, neutrophils decrease superoxide anion 
production and EC adhesion [175]. Another important reaction is increased secretion of VEGF 
by macrophages and EC, which is crucial in the process of tissue repair [173]. The protective 
role of Ado is also evidenced by the decrease of energy consumption in damaged tissue, which 
is mediated by a direct mechanism of inhibition. An example of this is the negative inotropic 
effect of Ado on heart muscle with ischemia, hypoxia or inflammation [172]. Furthermore, Ado 
indirectly protects cardiac tissue by increasing the availability of nutrients through 
vasodilatation [175]. Thus, Ado controls progression, intensity and time of an inflammatory 
process, by biochemical interactions with the immune system. 
 
Figure 31 - Interaction of adenosine with immune cells leading to inflammation control response. 
Adapted from [175, 176]. 
Cells capture Ado from the external environment, which is needed for intracellular 
synthesis of ATP. Bodin  and Burnstock in 1996 [177], studied the influence of extracellular ATP 
in HUVEC cells, and they showed that it induces the production and release of this energetic 
molecule, an important status in physiological and pathological conditions, as for example, in 
oxidative stress and hypoxia states. The same scientists [178] showed in 1991, that ATP release 
occurs exclusively in EC and not in muscle cells, and that the endothelial are the ones to 
respond in oxidative stress situations.  
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Ado and their derivatives, also display an important role in regulation of 
gastrointestinal function. Purinergic neurotransmitters mediate relaxation of gastrointestinal 
tract and bladder smooth muscle and, simultaneously, control secretions of intestinal mucosa, 
bowel fluid and electrolyte transport [179]. These mechanisms are intimately related to the 
down-regulation of activated immune response, mentioned above. Therefore, disregulation of 
these processes has pathophysiologycal consequences, such as, dysmotility, diarrhea and 
visceral pain [179]. 
Several disorders result from inborn errors affecting purine pathways and they are, 
usually, associated to enzymatic failures. Deficiency of several enzymes, such as, APRT (salvage 
of adenine to AMP), HGPRT (salvage of hypoxanthine and Gua into IMP and GMP, also called 
Lesch-Nyhan disease), ADA (conversion of Ado to Ino), purine-nucleoside phosphorylase (PNP; 
reversible phosphorylation of Ino and Gua), xanthine oxidase (XO; conversion of hypoxanthine 
into xanthine amino acid and then to UA) and ADSL (convertion of adenylosuccinate into AMP). 
Additionally, molybdenum cofactor deficiency (inability to synthesize a cofactor of XDH) leads 
to xanthinuria, hypouricemia and increased urinary sulfite [180]. 
Guanosine (Gua) is an important precursor of several energetic compounds, such as, 
GTP, GDP, GMT and cGMP [181], and it is considered as another protective agent due to the 
signaling modulating effect on cell growth, differentiation and survival [182, 183]. Jackson et al. 
[181], conducted several studies to observe the action of Gua in cultured cells of aortic and 
coronary artery vascular smooth muscle, coronary artery endothelial cells and cardiac 
fibroblasts. They reported that Gua, in the extracellular space, inhibits the availability of Ado 
and that this effect was neither attenuated by inhibition of certain enzymes, such as, ADK, ADA, 
SAH, or by Ado transport mechanism [181]. However, when the regulation of cell proliferation 
mechanisms was required, extracellular Gua increased Ado capacity through specific Ado 
receptors [184]. They also proved that certain metabolic toxins like iodoacetate and 2,4-
dinitrophenol inhibit glycolysis and oxidative phosphorylation reactions, which eventually 
increase extracellular concentration of Gua and Ado [181, 185]. Therefore, it is considered that 
guanosine has an indirect signaling and regulatory function on Ado. 
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1.3. Metabolic relationship between all de above-mentioned compounds  
Endothelial function and its homeostatic state are indicators of the risk of developing 
CVD. All molecules like Hcy, GSH, Ado, Ino or NO, which in high concentrations may induce 
activation of vascular endothelium or, shifts in metabolic pathways that, directly or indirectly, 
change physiological functions, are considered as risk factors. As previously mentioned, 
reactive species are essential secondary messengers on EC. However, an excessive increase of 
those compounds can cause changes with negative effects on the cardiovascular system, 
which lead to toxicity and development of pathological conditions.  
In conclusion, we emphasize some significant aspects and relationship between the 
compounds analyzed, expressed through the figure 32 and 33.  
Some studies have reported the relationship between Hcy transsulfuration pathway 
and GSH metabolism, which indicate that there are two sources of Cys, the transsulfuration 
pathway and import from external environment. It is also pointed out that about half of total 
GSH results from the metabolic pathway of Hcy, and the other half comes from external 
transportation and protein processing [186]. Weiss et al. [187], demonstrated that increased 
expression of GPx increases NO bioavailability and decreases adverse effects mediated by 
HHcy. 
Ado is considered to have protective characteristics at cardiovascular level. However, 
when there is an increase of plasma Hcy concentration, like in HHcy cases, Ado concentration 
decreases [188].  
Adenine nucleotides result from Ado and PRPP in the presence of APRT, requiring ADK 
and SAH. Thus, the relationship between Ado and Hcy is clear, as represented in figure 33. 
Seley et al. [189], reported that guanosine fleximers, nucleoside analogue molecules, inhibit 
SAHH, the enzyme that catalyzes SAH into Ado and Hcy, activity. 
 
Glycolysis is a source of Ser for folate cycle and a major source of energy in ATP form, 
which is essential for cell proliferation and biosynthesis reactions. Recently, it was discovered 
that this pathway is crucial to angiogenesis and that a partial reduction of this route has 
favorable effects on inhibition of pathological angiogenesis, like in tumor conditions [89]. 
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Figure 32 - Schematic representation of the metabolic relationship between the studied compounds. 
 
 
Figure 33 - Purine metabolism emphasizing the link with homocysteine pathway. Adapted from 
Baranowska-Bosiacka et al. [150].  
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2. Analytical Determination of Thiol Compounds 
2.1. Methods for compound identification and quantification  
So far, numerous techniques and procedures for qualitatively and quantitatively 
determination of thiol compounds, have been developed. On the one hand, it reflects the 
great interest on these compounds for clinical diagnosis. On the other hand, it demonstrates 
the great difficulty that it is to find an effective method for detecting a metabolic group of 
thiols. Besides being complex analyses, data interpretation and pathological relationship is not 
easy [104]. Nowadays, the separation and identification are possible thanks to innovative 
technologies, precise and with a high resolution, as listed in table 2. Each one has advantages 
and disadvantages that must be taken into account when choosing the analytical procedure 
[104]. However, it is important to remember that thiol compounds and their derivatives are 
oxy-reducible, very unstable and therefore of difficult quantification [190]. 
Table 2 - Analytical methods for biological markers [190, 193]:  
Methods Technical Specifications 
Chromatography 
Gas Chromatography-Mass Spectrometry (GC-MS) 
 Liquid Chromatography-Mass Spectrometry (LC-MS) 
Liquid Chromatography of 
High or Ultra Performance 
(HPLC or UPLC) 
Detection: 
Photometric (PDA) 
Fluorescence (FLR) 
Electrochemical (ED) 
Hydrophilic Interaction (HIC) 
Ionic Exchange  
Capillary Electrophoreses 
Detection: 
Photometric 
Fluorescence  
Immunoassays 
Fluorescence Polarization (FPIA) 
Chemiluminescence (ICL) 
Enzymatic (EIA) 
Colorimetric enzymatic assays 
Spectroscopic - Nuclear Magnetic Resonance (NMR) 
 
From the listed methods, mass spectroscopy (MS), used for identifying a wide range of 
compounds and with high reproducibility, stands out. This technique can be associated with 
gas chromatography (GC-MS), which is more suitable for the analyses of volatile organic 
compounds and derivatives of primary metabolites [190]. Also, it can be coupled to liquid 
chromatography (LC-MS), which is applied in a wide range of semi-polar and polar compounds 
without derivatization [190, 191]. 
Capillary electrophoresis is a technique that, just like with chromatography, uses a 
small sample volume and analyses takes place in a short time, with good resolution and uses 
little solvent in the run [192]. One disadvantage is the poor sensitivity when ultraviolet (UV) 
detection is used [193]. 
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Immunoassays, such as ELISA (Enzyme Linked Immunosorbent Assay), do not require 
such specialized equipment and are of high sensitivity and reproducibility [194]. However, the 
results are limiting as only metabolically reactive molecules are identified, for instance by 
antigen-antibody link or by enzymatic reactions. Another problem is the lack of standardization 
of trials and the high cost of reagents [190]. 
Nuclear magnetic resonance (NMR) is among the latest methodologies. The main 
advantage is that the analyzed sample is not destroyed, remaining viable for further analysis 
but, it has relatively low sensitivity [193]. 
The above-mentioned diversity of methods is due to the great need to find biomarkers 
of different pathologies for biochemical and molecular investigation. In these areas of research, 
the great clinical interest requires simple automated methodologies, very sensitive and 
accurate, which fit the routine work of the clinical pathology laboratories [195]. Thus, the 
scientific community has applied these powerful tools, in order to define metabolites and 
related compounds important in understanding mechanisms and in diagnosis and prognosis of 
pathologies [193]. 
 
2.1.1. Chromatography  
 Among the several methods that may be used for determination and quantification of 
thiol compounds, and their metabolic products, chromatographic methods are currently, the 
most used, since they are very versatile. They allow different forms of sample handling and 
many analytical conditions can be applied, besides different detection parameters as will be 
specified further on. A major advantage of this technique is the possibility of detecting 
multiple compounds in a single analysis, with a high specificity and sensitivity [196]. However, 
the main difficulty of analysis is associated with physicochemical properties of thiol 
compounds. They are highly unstable and reactive molecules so, they require cautionary 
measures throughout sample treatment. Taking all these factors into account, liquid 
chromatography was considered as one of the best methods to fit the goals of the presented 
work. 
2.1.1.1. History and Evolution 
Chromatography was set up at the beginning of the year 1900, describing a 
colorimetric experience characterized by the separation of a mixture of compounds distributed 
between two or more immiscible phases (gaseous, liquid or solid).  
It is a dynamic method in which the components are separated between two phases, 
one fixed (stationary phase) and another one that moves relatively to it (mobile phase) [197]. 
Liquid chromatography is the science that allows separating, identifying and quantifying 
compounds that are in a liquid sample. This technique involves the injection of a small sample 
volume into a column packed with porous particles. The individual components carried along 
the column by a liquid solvent move by gravity or pressure [198]. The components of interest 
are separated from each other due to the chemical and physical interactions established with 
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the column packing material. The separated compounds are detected and identified by output 
external measurement techniques. Since the development of the first chromatographic system, 
this method became one of the most powerful tools in analytical biochemistry [197, 198]. 
The first separative chromatography demonstrations date back to 1860, but only in 
1902 the botanist Tswett described the technique in his studies. He used a gravitational 
column (Classic method) and demonstrated its ability to separate different compounds in 
plants extracts. Years later, in 1941 Martin reported that the most efficient columns must be 
composed of very small particles and withstand high-pressure differences throughout its 
length [197]. In the early 1950´s, the first-automated method that enabled the analysis of 
amino acid mixtures, by ion-exchange chromatography was described, which was considered 
an important precursor of the high-pressure liquid chromatography (HPLC) [197, 198]. The 
relevant theoretical foundations of this technology have been established until the 1960´s, 
which allowed, in the following years, the creation of the commercially known HPLC 
equipment patented by the company Water Associates, which so far dominates the market 
[198, 199].  
In the pre-HPLC period, the results were obtained after a two-hour run, but the 
progressive improvement already achieved in 1970, allowed reduction of the run time to 15 
minutes. Since 1980 until today, the method has developed so much that in just a few seconds 
it is possible to obtain a specific chromatogram of a mixture of compounds [198]. The company 
now renamed Waters Corporation, states that the improvement of results are due to 
reduction of the separation time and the increase of pressure in the column, a consequence of 
reducing the size of particles that constitute the column packing material [197]. They claim 
that the emergence of HPLC results from the urgency in analytical biochemistry results, within 
the Biotechnology, Pharmaceutical and Agrochemical Industry seeking fast, efficient and 
economic methods. Therefore, it points out that the technique has been set in order to obtain 
results in a short time [197, 198]. However, in 2004, the high analytical demands led to the 
development of ultra performance liquid chromatography (UPLC), a unique technology that 
combines the best attributes in speed, sensitivity and resolution in a chromatographic system 
[200]. This new approach involves simultaneously innovation, technology and design in a single 
instrument, designed to meet and overcome the challenges of laboratory analysis. These 
characteristics have been achieved by reducing the particle size of the stationary phase (1.7 – 
1.8 µM), compatible with many mobile phases and pressure limits up to 1030 bar (15.000 psi). 
This innovative system achieves ultra-fast analytical separation, with high yield and resolution 
in less time of analysis [197, 199].  
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2.1.1.2. Ultra Performance Liquid Chromatography System (UPLC®) 
 The chromatography equipment used was the ACQUITY UPLC® H-Class of Waters 
Corporation, shown in figure 34. Its main components are a quaternary manager solvent, a 
sample flow controller through a needle, tunable detectors and exchangeable separation 
columns. All this analytical chromatographic system is controled by the software Waters® 
EmpowerTM. 
 
Figure 34 - Characterization of the ultra performance liquid chromatography system ACQUITY UPLC® H-
Class of Waters Corporation. 
 
I. UPLC® operation system 
 This chromatographic system (figure 35) operates effectively, in order that a portion of 
the sample is pipetted, mixed in the solvent flow and transported to the column through a 
high-pressure flux. That injected mixture, crosses the column through the porous center and, 
at the output, the detector identifies fractions of constituents [201]. Subsequently, the signal is 
received and decoded by the computer system, reflecting it into peaks. The separation of the 
analytes is possible due to competition between the phases that make up the system. The first 
detected compounds have higher affinity for the mobile phase, moving faster through the 
column. The last, have higher affinity for the stationary phase and suffer greater retention [201, 
202]. Therefore, the essence of liquid chromatography lies in the travelling speed of 
compounds, which in turn is determined by the molecular characteristics of the sample, but 
also by the properties of the column packing material and reagents used as solvents. 
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Figure 35 - Schematic representation of the operation system UPLC®. Image obtained from [203]. 
 
II. Chromatographic analysis  
 The separated compounds are identified by external measurement techniques after 
their exit from the column. As previously mentioned, the specific bands of each analyte are 
detected and transmitted to the computer system. The detector when receiving that 
information identifies the band, in contrast with the mobile phase background and sends the 
signal to the software that translates in a chromatogram, a graphical representation of all 
chemical compounds that are possible to detect in the sample injected [203]. A band is 
characterized by two distinct zones, the central part with higher concentration of the 
compound, and the anterior and posterior edges with lower concentrations. These differences 
across a band are interpreted and translated at the peak and each peak expresses each 
compound identified, in a graph that reveals the concentration in arbitrary units relative to the 
run time [202, 203]. 
 The most important considerations about the chromatographic system UPLC® H-Class 
are: 
A. Column – A wide variety of columns can be used in this equipment and the choice is 
made according to the compounds that the operator wishes to identify. In this case, 
we opted for the ACQUITY UPLC HSS T3 (2.1 x 100 mm, 1.8 µm particle size) and the 
ACQUITY UPLC HSS T3 VanGuardTM (2.1 x 5 mm, 1.8 µm particle size) pre-column from 
Waters Corporation (Figure 36) [204]. It consists of spherical silica particles with 1.8 
µm of diameter, forming pores of 100 Å, bonding technology T3 that utilizes a 
trifunctional C18 alkyl phase. Particles have a high compatibility with aqueous mobile 
phase, perfect to retain and separate a wide range of polar organic compounds. 
Designed to have a high resistance (HSS – High Strength Silica) and ensure rapid 
separation with higher resolution. This way, it combines efficiency, robustness and 
high yield. It operates effectively in solvents at pH between 2 - 8, pressure above 
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18.000 psi (1241 bar or 124 MPa) and temperature ranging between 20 - 45 °C. The 
column contains an intelligent chip, which records the history of its performance and, 
at the same time, calculates the lifetime. It is considered one of the most advanced 
technologies in liquid chromatography [205, 206]. 
 
Figure 36 - ACQUITY UPLC HSS T3 (2.1 x 100 mm, 1.8 µm particle size) column linked to ACQUITY UPLC 
HSS T3 VanGuardTM (2.1 x 5 mm, 1.8 µm) pre-column and representative scheme of their connection. 
Image obtained and adapted from [204, 207].  
B. Detector - There are various types of detectors and all have the ability to reveal the 
presence of a specific compound in the analyzed sample. However, it is necessary to 
adjust each sample to the method, system conditions and reagents that are used. The 
detectors for UPLC® system have been designed, taking into consideration the 
physical and chemical properties of the analytes that can be identified and solvents 
that can be used [208]. The detectors differ in capture and translation of the received 
signal. There are fluorescence (FLR), photodiode array (PDA), electrochemical (EC), 
evaporative light scattering (ELSD), mass spectrometry (MS; SQD – Single Quadrupole 
Mass Spectrometry Detector and TQD – Quadrupole Mass Spectrometry Detector) 
and refractive index (RI) detectors, among others [208, 209]. Several features must be 
taken into account before choice, such as, the need of a rapid response with high 
sensitivity and reproducibility and, at the same time, to be specific and predictable. 
The detector should provide a dynamic response and express direct proportionality 
[208], in particular, the response should increase linearly with the increasing amount 
of analytes in the sample. The results should be translated in a qualitative and in 
quantitative way.  
Finally, something to keep in mind is that the results are affected by the pH of the 
sample and solvent, the system temperature, the flow rate and type of mobile phase used 
[208, 210]. 
 
Following, the main characteristics of two of the detectors used in the 
chromatographic system UPLC® H-Class: 
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B1. Photodiode array (PDA) – Characterized by ultraviolet and visible light (UV/Vis) 
spectrophotometer, illustrated in figure 37, that captures information between 190 - 
500 nm, with an optical resolution of 1.2 nm, transmitted by a matrix of 512 aligned 
photodiodes [211]. The flow cell of the column is similar to an optical fiber, coated 
with Teflon AF amorphous and chemically inert fluoropolymer [212]. When the 
mixture of mobile phase and sample pass the core of this section, the light from the 
deuterium lamp (D2 lamp – Hydrogen Isotope) is projected [211]. The refractive index 
of Teflon AF is lower that the aqueous mixture, so the light beams entering the liquid 
core are reflected and transmitted throughout its extension. The light coming out of 
the column through the silica pores is projected to the concave spectrograph 
(Diffraction Grating), which disperses and projects the received light to the photodiode 
array [211, 212]. Thus, the detector measures the amount of light that reaches the 
photodiode array and determines the absorbance of the sample in the flow cell. Each 
photodiode operates with a capacitor that retain a certain amount of charge, which 
when struck by light is released [211]. Therefore, the magnitude of the discharge 
depends on the amount of light that reaches the photodiode [208]. Subsequently, the 
detector measures the amount of energy needed in charging each photodiode, being 
proportional to the amount of light transmitted through the flow cell, for a given time 
interval [208, 211]. Therefore, the chromatographic results are given through a graph, 
where the absorbance units (AU) and the time (min) of analysis are expressed. In this 
type of detector, it is important to consider the possibility of some photometric errors. 
As such, the PDA experts report that to minimize these effects, the maximum spectral 
absorbance of a compound should never exceed 1 AU [211]. 
 
Figure 37 - Schematic representation of the ACQUITY UPLC Photodiode Array Detector operating mode 
in the UPLC® system. Interactive image taken from the chromatographic equipment used and adapted 
the information referred to in Waters Corporation publications [208, 212]. 
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B2. Fluorescence (FLR) – It consists in determining the optical light emitted by the sample, 
which is excited by a specific wavelength [208]. The detection process begins by 
filtration of the source light from the mercury and xenon lamp (Hg-Xe Lamp), through 
the excitation monochromator (Excitation grating and parabolic mirror) an optical 
device with selects the excitation spectrum [213, 214]. Afterwards, the selected 
wavelength comes into the opening flow cell, where the sample is excited for this high-
intensity light. In the axial length of this section, the energy reflected back and forth, 
doubling the length of the path, which in turn increases the sensitivity of the detected 
signal [213]. Subsequently, the light is emitted by the sample through the top cell to 
the emission monochromator (Emission grating and photomultiplier tube (PMT)), 
where the low energy intensity is captured, filtered and translated into a fluorescent 
signal [208, 213]. In this detection, schematized in figure 38, it is possible to distinguish 
two light paths, the optical excitation and the emission monochromator, capable of 
detecting multiple wavelengths between 200 - 980 nm and 210 - 900 nm, respectively 
[213, 214]. Therefore, the chromatographic results are given through a graph where 
the emission units (EU) and the time (min) of analysis are expressed. 
 
Figure 38 - Schematic representation of the ACQUITY UPLC Fluorescence Detector operating mode in 
the UPLC®. The yellow light corresponds to the excitation energy and in red the emitted by the sample. 
Interactive image taken from the chromatographic equipment used and adapted the information 
referred to in Waters Corporation publications [213]. 
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 Summarizing, the UPLC® system is very versatile and allows combining different 
separation parameters and detection so, it is currently one of the most used technologies. It is 
widely applied for the detection and identification of metabolite profiles related to various 
human pathologies and it is a powerful tool that identifies numerous biomarkers. Noteworthy, 
the UHPLC-PDA|FLR methods provide fast and excellent resolution results using low volume of 
sample and solvents, and for this reason it is also economic. Therefore, our chromatography 
assay had low environmental impact.  
 
2.1.2. Pre-analytical considerations 
 In order to select the best technique, besides the previously referred, one must know 
well the characteristics of compounds intended to analyze, such as, the polarity (hydrophilic or 
hydrophobic), the volatility, etc.  
Few UHPLC-PDA|FLR methods for thiol compounds identification, in biological fluids, 
have been reported. Experimental procedures for this type of compounds imply the pre-
treatment of samples, such as, deproteinization, reduction reactions and derivatization. 
In the preparation of stock solutions of thiol compounds, some studies have reported 
that the formation of disulfide bonds promoted in basic medium [215]. So, they oxidize easily 
in alkaline solution. Furthermore, they suffer photo [216] and thermal [217] degradation, as 
such, throughout all procedures they should be kept protected from light and refrigerated 
around 0 °C, because they are more stable.  
To ensure stability of thiol compounds throughout the process of chromatographic 
analysis, reduction of disulphide bonds is a crucial step. For that purpose, the addition of a 
reducing agent was required. Due to its properties and good results presented in numerous 
reports, tris(2-carboxyethyl)phosphine hydrochloride (TCEP·HCl) (C9H15O6P·HCl) has been 
tested [218]. It results from the hydrolysis of the compound tris(2-cyanoethyl)phosphine in an 
acidic medium. It is reported to be a good reducing agent since it has high specificity for thiol 
compounds, large reactive capacity, even at low concentrations, is less sensitive to 
temperature changes and ensures better reproducibility and robustness of the tests [219]. 
Besides, it is water soluble, stable in acidic or basic medium, resistant to oxidation by air, 
odourless, non-volatile and has low toxicity. TCEP-HCl is considered more effective than other 
reagents on the market, such as, dithiothreitol (DTT) and 2-mercaptoethanol [219, 220]. 
Tributylphosphine (C12H27P), also known as TBP, is another reducing agent, which has an 
identical action to TCEP·HCl mentioned above but it is considered less effective and was also 
tested. It is a colorless reagent with amine odor [221] and, sometimes, it must be dissolved in 
dimethylformamide, a toxic solvent [219], which requires great caution. 
 The derivatization of thiol compounds is an exclusive and crucial step for their 
detection by FLR. The fluorescence of certain molecules results from light absorption in a 
specific wavelength that promotes their rise to a higher energy state. Later, when they return 
to their normal state, the excited molecules release the adsorbed energy in the form of 
photons [213]. The organic compounds analyzed in this work, do not naturally have that 
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characteristic, are able to absorb energy, but in the release they do not emit fluorescence. 
Therefore, it is necessary to perform labelling with a florescent molecule. As such, the 
derivatization reagent 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonic acid ammonium salt  
(C6H3FN2O4S·NH3), also colled SBD-F, which specifically reacts with the sulfhydryl group of thiol 
compounds, was considered as. It is water-soluble and the labeled compounds have an 
excitation wavelength between 380 - 385 nm and emission at 515 or 510 nm [222].  
It is important to consider that some parameters affect the reactive capacity of 
compounds, such as, pH changes that modify the electronic distribution of compounds with 
gain or loss of protons, which subsequently determines the intensity of the emitted signal. 
Furthermore, the fluorescence decreases with temperature increase and presence of oxygen 
dissolved in the sample [213]. 
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Chapter 2  
Experimental 
In this chapter, experimental protocols will be described in detail. 
2.1. Reagents 
During this work, reference compounds of analytical grade: L-glutathione (GSH), DL-
homocysteine (Hcy), L-homocystine (2Hcy), L-cysteine (Cys), cysteamine (Cyst), adenosine 
(Ado), inosine (Ino), as well as, the reducing agents tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP·HCl) and tributylphosphine (TBP), ammonia, boric acid, and the 
derivatizing agent 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonic acid ammonium salt (SBD-F) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). HPLC grade solvents: acetonitrile 
(ACN) and methanol (MeOH) from Fisher Scientific (Lisbon, Portugal), and formic acid (FA) 
from Panreac Química (Barcelona, Spain).  
Water was purified by a Milli-Q Integral purification system from Millipore Corporation 
(Billerica, MA, USA) under the following conditions: 18 MΩ cm at 25 °C. 
2.2. Equipment 
UHPLC analysis was carried out in an ACQUITY UPLC® H-Class System, combined with a 
Waters ACQUITY Quaternary Solvent Manager (QSM), an ACQUITY Sample Manager (SM), a 
column heater and a degassing system. Two chromatographic columns: the HSS T3 (2.1 x 100 
mm, 1.8 µm particle size) and HSS T3 VanGuardTM (2.1 x 5 mm, 1.8 µm particle size) pre-
column; the BEH C18 (2.1 x 150 mm, 1.7 µm particle size) and BEH C18 1.7 µm VanGuardTM (2.1 x 
5 mm column) pre-column, were employed. Two detectors were used: Photodiode Array 
Detector (PDA) and the Fluorescence Detector (FLR). The whole chromatographic system was 
driven by Empower Software v2.0, also from Waters Corporation (Milford, MA, USA). 
A vacuum filtration system with polytetrafluoroathylene (PTFE) membrane filters (0.22 
µm) was used for solvents and syringes with disposable filters of the same type of membrane 
porosity, for samples. All obtained from Millipore Corporation (Billerica, MA, USA). 
 
2.3. Preparation of solutions 
2.3.1. Standard solutions 
Stock solutions of GSH (2.00 mM), Hcy (7397 µM and 2.00 mM), 2Hcy (2.00 mM), Cys 
(100 mM and 2.00 mM), Cyst (2.00 mM), Ado (2500 µM) and Ino (2500 µM). Briefly, 10 mg Hcy 
was dissolved in 10 mL of acidified Milli-Q water with 0.4% FA [223]. 3.07 mg GSH, 1.21 mg Cys, 
2.35 mg Cyst were all dissolved in 5 mL of acidified Milli-Q water with 0.04% FA. 
In order to evaluate the stability of standards and to maintain free sulfhydryl groups, 
several conditions were tested including the use of 0.04% FA and 0.04% boric acid. Standard 
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solutions used in the elaboration of calibration curves of thiols, were prepared from the above-
mentioned stock solutions by dilution in the mobile phase used or in acidified Milli-Q water. 
The concentrations of GSH, Cys, Hcy and Cyst ranged from 5.00 to 100 µM, and of Ado and Ino 
from 25.0 to 500 µM. 
Ado 500 µM solution resulted from the dilution of a pre-existing 5000 µM stock 
solution. It was prepared by diluting 500 µL of this stock solution with Milli-Q water, to obtain 
a 5 mL solution. Ino 2500 µM solution was obtained by weighing 3.35 mg and dissolving with 
Milli-Q water until obtaining a 5 mL solution. When necessary, a few drops of 0.1 M ammonia 
solution were added to these purine compounds, in order to achieve a clear solution.  
  
Solutions were all filtered with a PTFE membrane and preserved at -20 °C. 
 
2.3.2. Reducing agent 
 As described by Valente et al. [224], 5 mL of 390 mM TCEP·HCl was prepared in Milli-Q 
water. Subsequently it was also filtered with a PTFE membrane and aliquots were made and 
stored in eppendorf tubes at -20 °C [223]. 
TBP solution was used diluted 1:40 in the sample. 
 
2.3.3. Derivatizing agent 
The derivatizing agent used for thiols was SBD-F, prepared at 4.24 mM, weighing 1 g 
and dissolving in 1 L of Milli-Q water. 
 
2.4. Pre-analytical treatment performed in standard solutions 
2.4.1. Standard solutions of purines for UHPLC-PDA analysis 
 Ado and Ino at different concentrations, were injected directly in the chromatographic 
system, without any sample pre-treatment. 
 
2.4.2. Standards solutions of thiol compounds for UHPLC-FLR analysis 
Thiol compounds GSH, Hcy, 2Hcy, Cys and Cyst were previously labeled with a 
fluorescent molecule, the derivatizing agent SBD-F. 
Derivatization procedure consisted in mixing the standard solution with TBP and 
incubating for 30 minutes at 4 °C. Then, 100 µL of borate buffer and 50 µL of derivatizing agent 
SBD-F were added to 50 µL of the previous reduced mixture and it was incubated for 60 
minutes in a 60 °C water bath.  After this time, the tube was placed in an ice bath for 5 minutes. 
Finally, 2 µL was injected in the UPLC-FLR system. 
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 The entire procedure was carried out while maintaining and protecting eppendorf 
tubes from light, by covering them with aluminum foil, since thiols are photosensitive 
compounds.  
 
 2.5. Development and optimization of analytical methods 
A method for thiol analysis was developed on a UPLC® system consisting of a 
quaternary solvent manager, a sample manager and two tunable detectors, PDA and FLR. 
 The starting point of this research was based on the work previously developed by a 
former master student, Hugo Câmara in his dissertation [223]. We started using the same 
UHPLC techniques, which were modified in order to obtain the best results. 
  Preliminary experiences to optimize chromatographic separation of standard 
compounds involved testing several UHPLC conditions.  
Different mobile phase compositions, such as, Milli-Q water acidified with 0.1% formic 
acid (H2O|0.1%FA), ACN without or with FA acidification (ACN|0.1%FA) and MeOH without or 
with FA acidification (MeOH|0.1%FA), as well as, different pH conditions were assayed. Two 
chromatographic columns were tested, the HSS T3 and the BEH C18, protected with the 
respective pre-columns. Various injection volumes were analysed (2, 4, 6 and 8 µL), as well as, 
sample temperatures (4, 8, 10, 20, 23, 37 °C).  Several conditions of flow-rate (0.2, 0.3 and 0.4 
mL/min), time of analysis (5, 8 and 10 min) and equilibrating (1, 2, 5 and 10 min), were tested. 
2.5.1. Validation of methods 
Validation of an analytical method involves several procedures, which are necessary to 
show that it can be used in quantitative measurement of one or more analytes in a given 
biological matrix. Moreover, it must be reliable and reproducible [225]. Validation must be 
documented by the experimental work. Acceptability of an analytical data should be reflected 
in the parameters of validation [226]. In this case, there was an exploratory and internal 
research method with the expectation of promissory results, where validation was a 
requirement. 
With the purpose of validating our method, selected concentrations of calibration 
solutions were chosen according to equipment sensitivity and the concentration usually found 
in biological samples. In this study, the following analytical parameters were considered:  
The selectivity was measured by the absence of interfering compounds in analyte’s 
retention time. This ensures that the quantification of analytes is not affected by compounds 
used in sample treatment or by mobile phase constituents [226]. To measure this, the 
chromatogram from direct injection of standard solutions must be compared with the 
chromatogram from biological samples determining the absence of interference of analytes, 
on the desired retention time. Accordingly, it is considered that a method is specific when it 
allows discriminating compounds, providing assurance that a certain quantity comes only from 
the intended analyte [225]. 
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The linearity of the method expresses results directly proportional to the 
concentration of the compound and it is obtained by determining the correlation coefficient 
[225]. With this purpose, three calibration curves for each analyte, were carried out with six 
(or more) different concentrations of the compound prepared in acidified water, mobile phase 
or by derivatizing procedures. Each concentration was injected six times. It was estimated from 
the concentration range of the calibration curve, the lowest level (Low Level - LL), middle 
(Medium Level - ML) and higher level (High Level - HL) [226, 227]. The superposition of the 
different concentrations levels expressed the linearity of the method. 
The sensitivity was determined by the limits of detection (LOD) and quantification 
(LOQ) for each tested compound [227]. It is calculated by the lowest concentration level of the 
analyte in the linearity evaluation. LOD is calculated by 3 x standard deviation (SD), which is 
three times the noise in the baseline, and LOQ is obtained by 10 x SD, what is ten times greater 
than the baseline noise [226].  
The precision allows evaluating the dispersion of results between dependent tests, 
repeated on the same sample under the same conditions [225]. It is expressed by the relative 
standard deviation (RSD) obtained by injecting three concentrations - Low, Medium and High 
level calibration curves. Standards were analyzed six times on the same day (Intra-day) and 
reproducibility (Inter-day) was determined on three non-consecutive days with replicas of 
different concentrations [226, 227]. Within this parameter are the repeatability and 
reproducibility. 
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Chapter 3 
 Results and Discussion 
 
Throughout this chapter, the most relevant results obtained during the development 
of the UHPLC method with FLR detection for identification and quantitation of some thiol 
compounds, and PDA detection of some purines are presented and discussed. 
 
3.1. Development and optimization of an analytical method for analysis of thiols by 
UHPLC with FLR detection. 
3.1.1. Thiol analysis by UHPLC with PDA detection 
In order to find an effective method for the detection of all thiol compounds (GSH, Hcy, 
2Hcy, Cys, Cyst), in a single run, some preliminary experiences were performed. 
Chromatographic conditions were tested in the UPLC® system, concerning the mobile phase 
composition, type of column, flow-rate, analysis and equilibrating times, injected sample 
volumes and column temperature. The main results obtained are reported below. Our 
chromatographic results corresponded to the data provided by the UPLC® system, for each 
injection performed. The identification of each compounds were expressed by the retention 
time (min) and by the peak intensity in AU or EU, whether the detection was by PDA or FLR. 
Thus, the intensity was translated by the peak area (µV°sec) and height (µV) Additionally, the 
spectrum obtained by PDA helped to confirm the identity of each peak.    
Firstly, thiol analysis by UHPLC with PDA detection was tried with the 
chromatographic conditions described by Câmara [223] for Hcy analysis. 
The results obtained with the UPLC-PDA method, were unfavourable like featured 
below in figure 39. The chromatograms showed peaks with poor resolution, low sensitivity and 
a great interference of the mobile phase, with a high background noise. 
 
Figure 39 - UHPLC-PDA chromatogram of a mixture of glutathione (100 µM) (A) and homocysteine (7397 
µM) (B).  
Several gradient conditions of the mobile phase were tested (see below). None gave 
good results. Peak overlap and doubled peaks were constantly obtained. More, in several 
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assays the chromatograms acquired with PDA detection evidenced large interferences of the 
mobile phases (figures 40 and 41) and poor sensitivities.  
 
Figure 40 - Spectra of analyzed glutathione (200 ± 4.7 nm) by the UHPLC-PDA method. For additional 
chromatographic conditions, see table on annex 1. 
 
Figure 41 - Spectra of analyzed homocysteine (238 ± 0.0 nm) by the UHPLC-PDA method. For additional 
chromatographic conditions, see table on annex 1. 
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I. Sample treatment procedure tested for standard solutions  
TCEP·HCl was tested as a thiol reducing agent, according to the work developed by 
Câmara [223], but using different chromatographic conditions as presented in annex 2. 
TCEP·HCl 1 mM was also assayed in several different chromatographic conditions, by diluting it 
in the mobile phase to exclude possible interferences.  
These chromatographic conditions showed to be more favourable than those 
previously tested, based on the conditions of Câmara [223], like featured below in figure 42. 
The chromatograms showed a better resolution of peaks, higher sensitivity and less 
interference from the mobile phase. 
 
Figure 42 - UHPLC-PDA injection of a mixture of thiol glutathione (100 µM) (A) and homocysteine (7397 
µM) (B). Chromatographic conditions presented in annex 2. 
However, the interference of the mobile phase and the low sensitivity persisted.  
Therefore, we concluded that the best procedure for identification of thiols would be a 
method with FLR detection, which is more sensitive. 
 
3.1.2. Thiol analysis by UHPLC with FLR detection 
Considering the previous results and the low sensitivity of the method, it was decided 
that FLR detection would be a better approach. 
One of the requirements for FLR detection is that the molecule to be analyzed emits 
fluoresce. Otherwise, it must be labeled with a fluorescent compound. Thiol compounds do 
not emit fluorescence as was confirmed by injecting standards in the UPLC® system with FLR 
detection, without derivatization (see the chromatographic conditions in the annex 3). As a 
matter of fact, these tests proved the need of derivatizating thiol compounds as referenced in 
[224, 228]. 
In order to optimize the UHPLC-FLR method, several analytical conditions were tested: 
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I. Mobile phase composition 
 
Different mobile phase compositions and pH conditions were tested as shown in 
tables 3 and 4. 
Table 3 - Different mobile phases tested in isocratic conditions with pH adjustments: 
Mobile Phase (%) 
Solvent pH* 
H2O|0.1%FA ACN|0.1%FA 
90% : 10% 2.60 
90% : 10% NaOH (1 mM) 2.90 
Mobile Phase (%) H2O|0.1%FA ACN 
90% : 10% 2.60 
90% : 10% 
NaOH (1 mM) 
1º 3.60 
2º 4.30 
3º 5.33 
90% : 10% NaOH (12 mM) 3.00 
95% : 5% 2.70 
95% : 5% NaOH (1 mM) 3.60 
Mobile Phase (%) H2O|0.1%FA MeOH 
90% : 10% 2.80 
Note: (*) Each pH determination was performed tree times; the average (± 0.03 to 0.05 variation) was 
determined and presented in the table above. 
The best approach for thiol separation was the use of a mobile phase in isocratic 
conditions. Following these conditions, several isocratic mobile phases were tested with pH 
adjustments as shown in the previous table. Methanol revealed to be worse than ACN in the 
mobile phase organic solvent composition, because it caused greater variations in peak 
retention times and areas (worse reproducibility). Therefore, ACN was elected as the organic 
solvent. 
Table 4 - Mobile phase conditions tested for chromatographic separation of thiols: 
Solvents (%)  
Results 
H2O|0.1%FA (%) ACN (%) 
90 10 
Figures 43, 44 and 45 95 5 
97.5 2.5 
 
Pre-treatment and derivatization of standards was performed as described ahead. 
After derivatization of thiol compounds with SBD-F and UHPLC analysis coupled to FLR 
detection, as presented in figures 43 and 44, for Cys and Hcy, respectively, good results were 
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obtained with mobile phases 95:5 and 97.5:2.5 (v/v), with good peak resolutions. For a 90:10 
(v/v), mixture, a poor resolution was obtained with emergence of double peaks.  
 
Figure 43 - UHPLC-FLR injections of cysteine (100 µM) with an isocratic mobile phase at (A) 
95%H2O|0.1%FA:5%ACN, (B) 90%H2O|0.1%FA:10%ACN and (C) 97.5%H2O|0.1%FA:2.5%ACN. 
 
Figure 44 - UHPLC-FLR injections of homocysteine (100 µM) with an isocratic mobile phase at (A) 
95%H2O|0.1%FA:5%ACN, (B) 90%H2O|0.1%FA:10%ACN and (C) 97.5%H2O|0.1%FA:2.5%ACN. 
However, the assays performed, demonstrated significant changes of peak retention 
times, heights and areas, both intra and inter-daily what might indicate that the compounds 
analyzed are very unstable. According to bibliographic sources, we might be dealing with 
ionogenic analytes, which means that the compounds analyzed have a pKa (see data in table of 
annex 4) close to the mobile phase pH. This fact, favors the appearance of different forms in 
solution [229]. This was clearly confirmed for GSH in tests performed with FLR detector. As 
presented in chromatograms of figure 45, GSH was very unstable when mobile phase 
composition was 97.5%H2O|0.1%FA:2.5%ACN. 
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Figure 45 - Four UHPLC-FLR chromatograms of glutathione (100 µM) using an isocratic mobile phase 
97.5%H2O|0.1%FA:2.5%ACN. 
The optimum separation conditions were achieved with a mobile phase consisting of 
Milli-Q water acidified with 0.1% formic acid and ACN in a 95:5 (v/v) ratio, with a pH between 
2.6 and 2.7. This choice is in agreement with previous studies, as reported by Valente et al. 
[224], where it was reported that an aqueous phase at pH of 2 maximizes the fluorescence 
intensity of Hcy and Cys thiol compounds. 
 
II. Stationary phase composition 
 
Two different columns were also tested in order to choose the stationary phase that 
best fitted the chromatographic separation of our compounds. The HSS T3 with the HSS T3 
VanGuardTM pre-column, and the BEH C18 with BEH C18 VanGuardTM pre-column. Their most 
relevant characteristics are presented in table of annex 5a. 
 
Results obtained for thiol analysis with the BEH C18 column (figure 46) were poor, with 
split or double, broad and tailing peaks. Therefore, the best chromatographic column was 
demonstrated to be the HSS T3, which showed good resolution and selectivity characteristics.  
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Figure 46 - Separation of mixture of thiols composed of GSH (1), Cys (2) and Hcy (3), (each 100 µM) in 
two columns (A) HSS T3 and (B) BEH C18 (Chromatographic conditions annex 5b). 
Table 5 - Chromatographic data obtained from separation of a mixture of thiols in the HSS T3 column:  
Data 
Retention time  Area Height 
min 
RSD 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
GSH 1.011 ± 0.002 0.17 135800.67 ± 3336.12 2.46 13841.67 ± 429.26 3.10 
Cys 2.238 ± 0.001 0.07 55069 ± 7628.64 13.85 9890 ± 1254.39 12.68 
Hcy 3.872 ± 0.002 0.07 99800.33 ± 14351.88 14.38 14886.33 ± 1987.16 13.39 
Note: average ± SD from three injections 
 
Our choice was also based on theoretical information, such as, the fact that silica is a 
material of high mechanical and thermal stability, great rigidity and of high efficiency in 
chromatographic separations [230]. It only has two limitations, the restricted pH range and the 
presence of residual silanol groups, which cause peak asymmetry when the injected sample is 
a basic one [231]. The manufacturers also report that in acidic medium at a pH lower than 2, 
there are ≡Si-O-Si≡ bonds forming in the skeleton of silica, which are responsible for 
maintaining organic groups on the silica surface immobilized and they are more susceptible to 
hydrolysis. In basic medium, above pH 8, the hydroxyl groups (OH-) react easily with residual 
silanol, promoting dissolution of silica. As a result, the chromatographic core of the column 
changes, leading to low efficiency and front peak broadening [231].  
The HSS T3 column revealed to be more appropriate because the pH of the mobile 
phase was within the pH limits of the column. 
 
III. Temperature 
 
The sample manager temperature (°C) is an important parameter, as it ensures the 
stability of samples intended to be analyzed. In the UPLC-FLR method the conditions tested 
were 4, 8, 10 and 37 °C. Temperatures of the laboratory fluctuated between 23 °C and 30 °C. 
This was a critical point mainly for thiol compounds, which are more sensitive to oxidation 
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processes. In fact, it has been reported that the lifetime of thiol molecules decreases with 
increasing temperatures and basic pH of the solutions [232]. Taking that into account, the 
sample manager was set at 10 °C.  
 
The column temperature (°C) is a specific parameter related to the stationary phase 
composition, whose limit is set by the manufacturer. As presented in table of annex 5a, the 
maximum temperature for HSS T3 column is 45 °C. This is one of the factors, which determines 
peak retention times in a chromatographic run. In our study, the HSS T3 column temperature 
was maintained at 30 °C for all assays. A balance between stability of compounds and 
laboratory temperature was made. At this temperature, viscosity of the mobile phase 
decreases, which consequently, reduces pressure in the column and promotes diffusion of the 
sample originating narrower and higher peaks [233, 247].  
 
 
IV. Analysis and equilibrating times 
 
Run and equilibrating times were tested and showed similar results in the UPLC-FLR 
method for thiol compounds and in the UPLC-PDA detection for purines. 
The run time (min) parameter is the time taken for a complete chromatographic 
analysis, for each portion of sample injected. In our method, the run time was tested 
considering the type of mobile phase used and the retention time expected for every 
compound. Thus, 5, 8 and 10 minute runs, were tested. In the end, a good resolution was 
obtained with a fast 5 min analysis time. 
The equilibrating time (min) is also an important parameter to take into account in a 
chromatographic analysis. Considering the type of mobile phase used, 1, 2, 5 and 10 minutes 
equilibration between injections, were tested. 
Suppliers recommend that initial column equilibration should be made with, at least 10 
column volumes of the mobile phase used. In this case, the HSS T3 column needs at least 4 mL 
(4000 µL) [234]. However, by the observation of the obtained results it was assumed that 1 
min between injections was an adequate time . It is considered that a complete 
chromatographic cycle starts when the sample is injected and ends with the restoration of the 
pre-analytical conditions. Therefore, the run time plus the equilibrating time, totalized 6 
minutes. These conditions, allowed us to obtain good chromatographic results. 
 
V. Sample treatment procedure tested for standard solutions  
 Taking the above results of thiols (Hcy and GSH), previously reduced with TCEP·HCl (1 
mM) and analyzed by UHPLC with PDA detection, into account and the need to use FLR 
detection, it was necessary to previously derivatize standards. The derivatization reaction, 
transforms molecules that do not have fluorescent properties into fluorophore derivatives. 
The chosen derivatizing agent was SBD-F according to [235]. Before this action, it was 
necessary to reduce thiol dimmers and TBP was the chosen reducing agent according to this 
derivatization agent.  
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 After testing all the procedure steps and optimizing derivatization conditions, the 
following chromatograms were obtained (figure 47 and table 6) after reduction with TBP 
followed by derivatization with SBD-F. A good resolution of thiols and sensitivity of the method 
were obtained. 
 
Figure 47 - Chromatographic results of the injection of cysteine (A) and homocysteine (B) at 2.00 mM, 
after reduction with TBP and derivatization with SBD-F. (See chromatographic conditions in annex 6). 
 
Table 6 - Chromatographic data obtained from homocysteine and cysteine: 
Data 
Retention time  Area Height 
min 
RDS 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
Hcy 3.773 ± 0.001 0.02 354870.50 ± 1595617.63  44.96 633295.83 ± 83962.88 13.26 
Cys 2.204 ± 0.003 0.12 814253.83 ± 50755.42 6.23 146767.04 ±7732.01 5.27 
Note: Average ± SD of six injections 
The thiol standard homocystine (2Hcy), the dimmer of homocysteine, was also 
analysed. The results are shown below (figure 48 and table 7). 
 
Figure 48 - UHPLC-FLR chromatograms of the thiol standards homocysteine (A) and homocystine (B) at 
10 µM. (See chromatographic conditions in annex 6).  
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Table 7 - Chromatographic data obtained from identification of thiol standard homocysteine and 
homocystine at 10 µM: 
Data 
Retention time  Area Height 
min RSD (%) µV°sec RSD (%) µV RSD (%) 
Hcy (A) 3.528 ± 0.005 0.13 8056.16 ± 1128.26 14.00 1230.67 ± 134.26 10.91 
2Hcy (B) 3.530 ± 0.002 0.08 7762 ± 938.42 13.24 1148 ± 144.14 13.75 
Note: Average of six injections (mean ± SD) 
These results confirmed that reduction of thiols by TBP was effective. Derivatization 
was done with SBD-F and posterior UPLC-FLR analysis. 
 
3.1.3. Optimal chromatographic conditions for thiol analysis 
The optimal chromatographic conditions for the analysis of GSH, Hcy, Cys and Cyst 
thiols are shown in table 8.  
Table 8 - Optimal chromatographic conditions achieved for the determination of thiol compounds: 
Optimal chromatographic conditions 
Injection volume 2 µL 
Sample manager temperature 10 °C 
HSS T3 column temperature 
(100 mm x 2.1 mm, 1.8 µm particle size)  
30 °C 
Excitation wavelength 385 nm 
Emission wavelength 515 nm 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 1 min 
Mobile phase - Isocratic  
pH 2.6 - 2.7 
95% H2O|0.1%FA : 5% ACN 
Below, a chromatogram of a mixture of GSH, Cys and Hcy standards, obtained with the 
above conditions, is shown.  
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Figure 49 - Optimal conditions for the chromatographic analysis of a mixture of thiols glutathione, 
cysteine and homocysteine (each 100 µM), with FLR detection.   
The precision of the method was evaluated by repeated analysis (n=3) of the standards 
mixture, as shown in table 9. 
Table 9 - Chromatographic data obtained from separation of a mixture of thiols glutathione, cysteine 
and homocysteine (each 100 µM): 
Data 
Retention time  Area Height 
min 
RSD 
(%) 
µV°sec RSD (%) µV 
RSD 
(%) 
GSH 0.655 ± 0.005 0.26 1501726.33 ± 4355.30 12.05 150467.67 ± 320.58 11.49 
Cys 2.189 ± 0.000 0.03 355893.67 ± 7628.64 9.87 69398 ± 1254.05 8.94 
Hcy 3.752 ± 0.001 0.03 1926833.33 ± 14351.88 9.06 288050.67 ± 1987.16 8.76 
Note: average of three injections (mean ± SD) 
 
3.2. Development and optimization of an analytical method for analysis of purines by 
UHPLC with PDA detection. 
Several tests that proved that the PDA detection would be the best approach for 
purines were performed, since they are very stable compounds and absorb in the UV/VIS 
region, being good chromophores. 
Purines (Ino and Ado) were not subjected to any sample pre-treatment (see the 
biochemical and molecular characteristics in annex 8). Stock solutions were diluted in purified 
water and the desired concentration was directly injected in the chromatographic system. 
In order to find an effective method for detection of the purine compounds, in a single 
run, several conditions were previously tested based on the conditions reported by Câmara 
[223] and Araújo [236]. The main chromatographic conditions and results obtained with PDA 
detection are reported below.  
Firstly, the UV-Visible absorption spectra (190 to 400 nm) were obtained for both 
purine compounds, Ado and Ino. The diagram below shows the absorbance units (AU) versus 
the wavelength (nm), what translates the amount of radiation absorbed by each specific 
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compound. The highest absorbance value determines a particular wavelength at which 
chromatograms should be extracted. 
 
Figure 50 - Verification of the specific wavelength detection and spectrum of adenosine (254 ± 2.8 nm). 
(Chromatographic conditions used are listed in the table of annex 9). 
 
Figure 51 - Verification of the specific wavelength detection and spectrum of inosine (250 ± 1.8 nm). 
(Chromatographic conditions used are listed in the table of annex 9).   
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The UV-Visible absorption spectrum is specific for each compound and it is very 
important for the identification of analytes in a mixture of standards or in biological samples 
[237]. In the several analyses that were conducted, identification of different compounds was 
achieved by confirming retention times (min) and absorption spectra (nm).  
 
 
I. Mobile phase composition 
 
Initially, purine analysis by UHPLC with PDA detection was tested using the 
chromatographic conditions described by Câmara [223], for Hcy analysis. The results were 
unfavorable although without mobile phase interferences (see annex 10). Several mobile 
phase compositions were tested both in gradient and isocratic conditions (table 10), as well as, 
pH variations (table 11) until the best chromatographic separation of compounds was obtained. 
 
Table 10 - Mobile phase conditions tested for chromatographic separation of purines: 
Solvents (%)  Results 
H2O|0.1%FA : ACN|0.1%FA 
Different Gradients  
See annex  11 
90% H2O|0.1%FA : 10% ACN 
95% H2O|0.1%FA : 5% ACN 
Isocratic with pH variations 
Table 11  
H2O|0.1%FA (%) ACN|0.1%FA (%)  
90 10 Data not shown 
H2O|0.1%FA (%) ACN (%)  
90 10 Data not shown 
95 5 Figure 52 
97.5 2.5 Data not shown 
80 20 
Data not shown 70 30 
50 50 
H2O|0.1%FA (%) MeOH (%)  
90 10 Figure 53 
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Table 11 - Different mobile phases tested in isocratic conditions with pH adjustments: 
Mobile Phase (%)  
Solvent pH* 
Results 
H2O|0.1%FA ACN|0.1%FA 
90% : 10% 2.60  
Data not shown 90% : 10%  
NaOH (1 mM) 
2.90 
Mobile Phase (%)  H2O|0.1%FA ACN Results 
90% : 10% 2.60  
Data not shown 
90% : 10% 
NaOH (1 mM) 
1º  3.60  
2º  4.30  
3º  5.33 
90% : 10%  
NaOH (12 mM) 
3.00  
95% : 5% 2.70 
Figure 52 95% : 5% 
NaOH (1 mM)  
3.60 
Mobile Phase (%)  H2O|0.1%FA MeOH Results 
90% : 10% 2.80 Figure 53 
Note: (*) Each pH determination was performed tree times; the average (± 0.03 to 0.05) was 
determined and presented in the table above.  
 
The best approach for purine separation was also in isocratic mode. Following these 
conditions several isocratic mobile phases were tested with pH adjustments, as shown in the 
previous table.  
Figure 52 shows the UPLC-PDA chromatographic results of Ado using a mobile phase of 
95% H2O|0.1% FA : 5% ACN, at two different pH: 2.70 and 3.60. The small increase in the 
mobile phase pH caused a quite greater retention of the analyte on the column, what obliged 
to increase the run time. This would be disadvantageous, since the method should be fast and 
efficient, with results obtained in the shortest time. In accordance, the lowest pH was chosen 
for the mobile phase. 
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Figure 52 - UHPLC-PDA chromatograms of adenosine (150 µM), using an isocratic mobile phase 
95%H2O|0.1%FA : 5%ACN at pH of 2.70 (A) and 3.60 (B). 
Table 12 - Chromatographic data obtained from separation of adenosine in isocratic mobile phase 
95%H2O|0.1%FA : 5%ACN with pH variation: 
Data 
Retention time Area Height 
Maximum 
absorbance  
min 
RSD 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
AU 
RSD 
(%) 
Ado 
(A) 
2.070 ± 0.000 0.03 
2954632 ± 
214576.11 
1.22 
1231716.51 ± 
116309.89 
0.02 1.28 ± 0.10 0.32 
Ado 
(B) 
4.257 ± 0.005 0.13 
4028040.33 ± 
52799.88 
1.31 
914433.33 ± 
5396.15 
0.59 0.98 ± 0.01 0.97 
Note: average of three injections (mean ± SD) 
 
Methanol was tested as the organic solvent in mobile phase composition. However, it 
revealed to be worse than ACN, causing greater variations in peak retention times and areas. 
The results, as presented in figure 53. Chromatograms of standards showed no reproducibility 
(at least five injections) concerning peak retention times, areas and heights. Therefore, ACN 
was the elected organic solvent.  
 
 
Figure 53 - Overlap of inosine (125 µM) chromatograms using an isocratic mobile phase with methanol. 
(See chromatographic conditions in annex 12). 
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After testing the various mobile phase compositions it was considered that the 
following solvent composition: 95% H2O|0.1%FA : 5% ACN (v/v) was the best choice for our 
analytical procedure. 
 
 II. Stationary phase composition 
Two different columns were also tested in order to choose the one that best fitted the 
chromatographic separation of compounds: the HSS T3 and the BEH C18. Their most relevant 
characteristics are presented in table of annex 5. 
Both columns were appropriate although the results obtained indicated that the BEH 
C18 was even more suitable for purines detection as shown in figure 54, 55 and 56 for Ino, Ado 
and their mixture, respectively. A good resolution and sensitivity were obtained. Additionally, 
the column suitability was based on the theoretical information mentioned above for thiol 
compounds as the standards Ado and Ino presented a pH of 10.3 and 10.6, respectively. 
However, the HSS T3 was chosen, once it was being used for analysis of thiol compounds. 
 
Figure 54 – UHPLC-PDA chromatograms of inosine (250 µM) with (A) HSS T3 and (B) BEH C18. (See 
chromatographic conditions in annex 13). 
 
Figure 55 – UHPLC-PDA chromatograms of adenosine (250 µM) with (A) HSS T3 and (B) BEH C18. (See 
chromatographic conditions in annex 13). 
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Figure 56 – UHPLC-PDA chromatograms of adenosine and inosine (500 µM) with (A) HSS T3 and (B) BEH 
C18 both at 254 nm. (See chromatographic conditions in annex 13). 
 
Table 13 - Chromatographic data obtained from separation of adenosine and inosine (500 µM) with (A) 
HSS T3 and (B) BEH C18: 
Data 
Retention time Area Height 
Maximum 
absorbance 
min 
RSD 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
AU 
RSD 
(%) 
Ado (A) 2.245 ± 0.044 0.00 
168297 ± 
4579.33 
1.53 530499 ± 3065.7 2.96 0.97 ± 0.01 0.64 
Ino (A) 2.630 ± 0.108 0.02 
473153 ± 
2109.62 
1.44 128595 ± 5453.14 3.15 0.23 ± 0.01 2.53 
Ado (B) 0.928 ± 0.000 0.06 
5339191.67 ± 
12828.04 
0.24 
2510863 ± 
5794.17 
0.23 2.54 ± 0.00 0.06 
Ino (B) 1.015 ± 0.001 0.10 
2527239.67 ± 
451336.85 
17.86 
1218950.33 ± 
24461.39 
2.01 1.05 ± 0.01 0.74 
Note: average of three injections (mean ± SD) 
 
 III. Injection volume 
The injection volume (µL) of samples to be analyzed by UPLC should be proportional to 
the volume of the column used. This parameter is important for the stability of the 
chromatographic column and it was tested considering the type of sample and mobile phase 
used. As presented, injections of 2, 4, 6 and 8 µL of sample, were tested. 
What should be taken into account, before defining the injection volume is the void 
volume of the column [238], which corresponds to the amount of space that is not taken up by 
the peaking material. It is theoretically calculated using the equation represented in figure 57. 
The calculation considers the dimension of the column. The HSS T3 column of 2.1 x 100 mm, 
has a void volume equal to 240 µL (or 0.24 mL). It is assumed that an average value for the 
pore volume is 0.70 (70 %) for a bare silica support [238]. 
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Figure 57 - Theoretical equation for the calculation of the empty space of a chromatographic column 
[238]. Alternatively, it is presented as: Column Void Volume (µL) = (d2(mm)*Pi*L(mm)*0.7)/4 [239]. 
  
 Regarding HSS T3 column, 240 µL is the empty volume that can be occupied by 
solution. Considering the run and equilibrating times already defined for thiol compounds, the 
5 min run plus 1 min of equilibrating and a constant flow-rate of 0.200 mL/min, it is estimated 
that 1200 µL is the total mobile phase volume that crosses the column during a complete 
chromatographic cycle. This estimate is important to realize the amount of solvent and sample, 
which should pass through the column during the chromatographic analysis. Therefore, it is 
important not to overload the column with sample and ensure that the running and 
rebalancing times are enough to clean and stabilize the chromatographic system for a new 
injection.  
Chromatograms, obtained through analysis by UHPLC with PDA detection for the 
standard inosine can be seen below. It was observed that the increase of injected volume, 
affected proportionally and directly the area and height of the peaks without changing the 
retention time. The concentration of the compound in the sample is always constant but, 
increasing the injected volume means that a greater amount of molecules are introduced into 
the column and are present in the analyzed portion so, resulting in greater intensity of peaks. 
The increase of the injected volume is reflected in broader peaks, what affects the 
chromatographic separation.  
 
Figure 58 - Overlap of chromatograms of different injected volumes, 2 (red), 4 (blue), 6 (green) and 8 µL 
(black), of inosine (500 µM) detected at 250 nm. (See chromatographic conditions in annex 13). 
 
To better understand how the injected sample volume affected the chromatographic 
results, data were treated (table 14), and the results are presented in figure 59. As expected, 
the results showed that the mean ± SD peak area and height, and absorbance increased 
proportionally to the increase of volume. 
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Table 14 - Variation of injection volume for standard inosine:  
Ino 
volume 
(µL) 
Retention time Area  Height  
Maximum 
absorbance  
min 
RSD 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
AU 
RSD 
(%) 
2 2,465 ± 0.001 0.06 231374,67 ± 108.16 4.67 39632,33 ± 1830.74 4.62 0,08 ± 0.00 4.75 
4 2,482 ± 0.000  0.02 1186041 ± 77004.48 6.49 208615,67 ± 12108.64 5.80 0,40 ± 0.02 5.26 
6 2,488 ± 0.000 0.00 2541412,33 ± 136770.16 5.38 420419,67 ± 2911.59 6.95 0,76 ± 0.05 5.95 
8 2,504 ± 0.000 0.02 4200363,67 ± 131754.08 3.14 730176,67 ± 24104.01 3.30 1,13 ± 0.01 1.02 
Note: Average of tree Injections (mean ± SD) 
The graphical representations in figure 59, allow us to compare the different results 
obtained for the four volumes tested. The absorbance and the intensity of the peaks increased 
approximatelly 0.3 AU as the injection volume rised. 
 
Figure 59 - Graphical representation of the chromatographic data obtained for inosine when testing 
injection volume. 
Considering the above results it was assumed that the most suitable sample volume of 
injection for this analysis, was 2 µL. It was enough to achieve good results, without overloading 
the column and maintaining the system pressure stable. 
 
IV. Temperature 
The sample manager temperature (°C) ensures the stability of samples as mentioned 
above for thiol compounds. In the UHPLC-PDA method for purine compound analysis, the 
conditions tested were 4, 8, 10, 20, 23 and 37°C. Purine compounds showed to be quite stable 
in this range of temperatures. 
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3.2.1. Optimal chromatographic conditions for purine analysis 
The optimal chromatographic conditions for the analysis of purines were achieved 
using PDA detection and are shown in Table 15. A chromatogram of Ado and Ino is presented 
in figure 60 showing results obtained with this method 
Table 15 – Optimal chromatographic conditions achieved for the analysis of purines and related 
compounds:  
Optimal chromatographic conditions  
Injection volume 2 µL 
Sample manager temperature 10 °C 
HSS T3 column temperature 
(100mm x 2.1mm, 1.8µm particle size)  
30 °C 
Specific UV wavelength 
detection 
Ado 254 nm 
Ino 250 nm 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating  time 1 min 
Mobile phase - Isocratic 
 pH 2.6 – 2.7 
95% H2O|0.1%FA : 5% ACN 
 
 
Figure 60 - Optimal conditions for the chromatographic analysis of inosine and adenosine (500 µM) with 
PDA detection at 250 and 254 nm, respectively. 
Table 16 - Chromatographic data obtained from separation of inosine and adenosine: 
Data 
Retention time Area  Height  
Maximum 
absorbance  
min 
RSD 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
AU 
RSD 
(%) 
Ado 2.249 ± 0.001 0.06 
2201479.75 ± 
134283.82 
6.99 688259.51 ± 44416.44 6.45 0.88 ± 0.05 5.34 
Ino 2.584 ± 0.005 0.01 708557.75 ± 47006.22 6.63 203003.75 ± 14224.91 7.01 0.38 ± 0.03 6.85 
Note: average of six injections (mean ± SD) 
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3.3. Difficulties encountered during the optimization procedures of UHPLC-PDA and UHPLC-
FLR analytical methods 
A recurrent problem of our analyses was an absence of intra or inter-day precision in 
the obtained results. After testing and excluding possible interferences in all the analytical 
conditions, which could be related to pre-analytical procedures, the chromatographic results 
obtained continued to demonstrate constant variations in peak retention time, areas, height 
and intensities, both in PDA and FLR methods. 
All the pre-analytical procedures were tested and samples were injected using, at least, 
six replicates. The intra-assay and inter-assay precision were evaluated and results are shown 
below: 
 
 Intra-day results 
Mixtures of thiol standards, previously derivatized by the procedure already specified 
above, were injected. In some cases, a good reproducibility was evidenced but not in other 
cases.  
Variations in peak areas and heights were observed as shown in figure 61 for three 
injections of the same standard of cysteamine,. The overlap of chromatograms shows the 
great variation of peak height and areas despite the stability of derivatives.  
 
Figure 61 - Chromatographic results of three injections of cysteamine standard (42 µM) showing no 
intra-day precision. 
Table 17 - Chromatographic data obtained from separation of cysteamine showing no inter-day 
precision: 
Data 
Retention time Area Height 
min RSD (%) µV°sec RSD (%) µV RSD (%) 
Cyst 2.863 ± 0.001 0.03 20206 ± 3943.44 19.52 3207.67 ± 635.81 19.82 
Note: average of three injections (mean ± SD) 
 Similar results were obtained for the UHPLC-PDA method used in purine analysis, 
where in addition to variations in peak areas and heights, there were also fluctuations in peak 
retention times as shown in an inosine chromatogram featured in figure 62. For comparative 
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purposes, we present also the relationship with the inter-day tests, which will be mentioned 
later on. 
 
Figure 62 - Overlap of chromatographic results of three injections of inosine standard (100 µM), showing 
no intra-day precision. 
Table 18 - Chromatographic data obtained from separation of inosine without precision: 
Data 
Retention time Area  Height  
Maximum 
absorbance  
min 
RSD 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
AU 
RSD 
(%) 
Ino  3.607 ± 0.044 1.44 566846.67 ± 7255.33 1.97 122360 ± 3065.67 3.12 0.22 ± 0.07 2.85 
Note: average of three injections (mean ± SD) 
 
 Inter-day results 
The inter-day precision of purine compound analysis, by UHPLC with PDA detection, 
presented similar results to the intra-day precision, as featured in figure 63. These 
chromatograms indicated that the UPLC® system was not functioning properly, since this 
method was already applied by HPLC [236] with very good results. 
 
Figure 63 - Chromatographic results of three injections of inosine standard (100 µM) showing no inter-
day precision. 
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Table 19 - Chromatographic data obtained from separation of inosine showing no inter-day precision: 
Data 
Retention time Area  Height  
Maximum 
absorbance  
min 
RSD 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
AU 
RSD 
(%) 
Ino 3.159 ± 0.108  3.42 564109.24 ± 8173.67 1.45 118048.88 ± 5453.14 4.62 0.22 ± 0.01 5.24 
Note: average of sex injections (mean ± SD) 
 
The inter-day precision of thiol analysis was evaluated. Results are shown in figure 64 
below.  
 
Figure 64 - Chromatographic results of two injections of a mixture of standard thiols (100 µM) 
identifying GSH, Cys, Cyst and Hcy. 
 When calculating the precision (table 20) of the method, we verified that the 
coefficients of variation (CV or RSD) were too high [240].  The CV determines if the analytical 
method is precise for the individual measurements of an analyte, when the procedure is 
applied repeatedly to multiple aliquots of a single homogeneous sample [227]. CV values must 
be below 15%.  
Table 20 - Chromatographic results of the inter-day precision of a mixture of standards: 
Inter-day 
precision 
(%) 
Retention time Area  Height  
min RSD (%) µV°sec RSD (%) µV RSD (%) 
GSH 0.82 ± 0.242 29.49 1989449 ± 826555.54 41.55 194873.80 ± 77662.67 39.85 
Cys 2.215 ± 0.036 1.63 329806.76 ± 93277.11 28.28 63799.53 ± 18323.67 28.72 
Cyst 3.071 ± 0.054 1.77 8112.76 ± 1503.14  18.53 4393 ± 2796.91  63.67 
Hcy 3.814 ± 0.085  2.24 1884839 ± 555265.16 29.46  278089.22 ± 78875.62 28.36 
Note: average of sex injections (mean ± SD) 
 This method of analysis of thiol compounds, with previous derivatization with SBD-F, 
has been reported as being a precise method by HPLC in Minniti et al. [235],  Akgül et al. [241] 
and  Ferin et al. [242]. However, some studies report the addition of stabilizer agents, such as 
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hydrochloric acid [243], sodium phosphate [244] or acetic acid, to stop the derivatization 
reaction. 
 Some more tests were carried out to exclude the hypothesis of instability of thiol 
compounds, even after reduction and derivatization, as presented in the chromatograms from 
figure 65. Conflicting results were obtained. While it seemed that, over time, thiol compounds 
suffered degradation translated by the appearance of double peaks (the case of cysteine) and 
disappearance of GSH, posterior injections of the same derivatized mixture resulted perfectly, 
what made us suspect of malfunction of the UPLC® system. 
 
Figure 65 - Chromatographic results of inter-day injections of a mixture of standard thiols (100 µM) 
identifying GSH, Cys, Cyst and Hcy. 
 The UHPLC-FLR method showed poor reproducibility (table 21), which was attributed 
to UPLC® problems. 
Table 21 - Chromatographic result of the inter-day precision of a mixture of standard: 
Inter-day 
precision 
(%) 
Retention time Area  Height  
min RSD (%) µV°sec RSD (%) µV RSD (%) 
GSH --- --- --- --- --- --- 
Cys 2.131 ± 0.071 3. 37 85245.42 ± 6562.79  7.70 24752 ± 4470.33 18.06 
Cyst 3.284 ± 0.380  11.57 258320.87 ± 32883.67  12.73 53810.3 ± 4947.76  9.19 
Hcy  3.574 ± 0.245  6.85 541529.33 ± 88228.52  16.29 79926 ± 10081.87  12.61 
Note: average of six injections (mean ± SD) 
Despite having changed to a new HSS T3 column as a final attempt to overcome the 
described difficulties and, besides having obtained very well resolved peaks, precision was 
inconsistent and it was difficult to find the source of the problem.  
Also important to mention is that result variations were not constant. They occurred 
randomly, what made them even more difficult to identify. Exhaustive tests were always 
conducted, in order to identify the origin of these problems.  
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Subsequently, loss of linearity was observed as expressed in the calibration curve in 
figure 66. 
 
Figure 66 - Graphical representation of the inter-day calibration curves of adenosine (n=6). 
 
3.4. Validation of the analytical methods 
 Validation of an analytical method implies performing several tests to show that a 
particular procedure can be used for the measurement of one or more compounds in a given 
biological matrix. Moreover, it must be reliable and reproducible for the intended use, like 
clinical evaluation, for example [225]. The acceptability of data results depends directly on the 
criteria defined for the validation of the methods [226], as the parameters presented below. 
In this work, an exploratory research was performed, where validation was an 
important requirement. Therefore, an extensive laboratory work was done to verify the 
performance of the developed analytical method. 
In order to demonstrate the applicability of both UHPLC methods (with PDA and FLR 
detection), qualitative and quantitative analyses were performed in an attempt to validate 
them as presented below. 
 
 Linearity of the UHPLC-FLR method 
It was possible to obtain good calibration curves with the UHPLC-FLR method 
developed for thiol analysis, as presented in figure 67 and 68 for glutathione, cysteine and 
homocysteine in a concentration range of 5, 10, 25, 50 and 100 µM. However, the validation 
was not completed because reproducibility was inconsistent.  
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Figure 67 - Chromatograms obtained for the calibration curves of the mixture of thiol standards 
glutathione, cysteine and homocysteine. 
 
The calibration curves of glutathione, cysteine and homocysteine, built with mean 
peak areas extracted from chromatographic data (average of three injections for each 
concentration), showed good correlation coefficients as presented in figure 68. 
  
 
 
Figure 68 - Graphical representation of the calibration curves of glutathione, cysteine and homocysteine 
(n=3).  
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 Linearity of the UHPLC-PDA method 
The concentrations of the calibration solutions were selected according to the 
sensitivity of the equipment and concentration normally found in biological samples. 
Linearity is obtained by calculating the correlation coefficient of calibration curves for 
each analyte [225].  
Calibration curves from six replicas of six (or more) different concentrations were built 
for each standard. Finally, the superposition of the curves expressed the linearity of the 
methods. 
This validation parameter was only partially achieved because equipment failure did 
not allow concluding all the analysis needed. 
 It was possible to obtain good calibration curves with the UHPLC-PDA method of 
purine analysis, as presented in figure 69 and 70 for inosine and adenosine, in a concentration 
range of 25, 50, 75, 100, 250 and 500 µM. However, the validation was not completed, 
because some results were not consistent.  
 
Figure 69 - Chromatograms obtained for the calibration curve of a mixture of standard (A) inosine and (B) 
adenosine. 
 The calibration curves of Ado and Ino, built with mean peak areas extracted from 
chromatographic data (average of six injections for each concentration), showed good 
correlation coefficients as presented in figure 70.  
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Figure 70 - Graphical representation of the calibration curves of inosine and adenosine (n=6). 
 
 Selectivity 
Methods are considered specific when they enable discriminating compounds 
providing assurance that a certain quantity comes only from the intended analyte [226].  
The absence of interference from other compounds is measured for each analyte in 
their expected retention time. Selectivity ensures that the quantification of every analyte is not 
affected by the reagents used in sample pretreatment, in our case it was TBP and SBD-F, or by 
the mobile phase constituents, ACN and FA. This parameter was confirmed for both 
chromatographic methods, since there was no interference in chromatograms obtained from 
the analyzed standards. 
As validation was not concluded, no biological samples were analyzed. Therefore 
interferences from samples were not checked. 
 
 Sensitivity 
It is determined by the LOD and LOQ of each compound tested. These parameters are 
calculated by the lowest concentration that was used in the calibration curve. The LOD is the 
product obtained by multiplying the SD by three, which is three times the noise of the baseline. 
The LOQ is the product obtained by multiplying SD by ten what is ten times greater than the 
baseline noise [226]. 
 Therefore, for thiols the LOD was calculated based on the lowest concentration (5 µM 
and 25 µM, average of tree injections) of the calibration curve and the regression equations 
obtained. LOD and LOQ are presented in table 22. 
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Table 22 - Detection and quantification limits for standards detection with the established methods: 
Thiol compounds 
UHPLC-FLR 
Regression equations LOD (µM) LOQ (µM) 
GSH y=24687x-6190.1 0.35 1.17 
Cys y=1146.7x-1921.9 1.21 4.04 
Hcy y=7028.7x+2915.2 0.54 1.81 
Purine compounds 
UHPLC-PDA 
Regression equations LOD (µM) LOQ (µM) 
Ado y=4291.2x-6105.1 0.20 0.68 
Ino y=1438.9x-35968 1.44 4.82 
 
These parameters were quite higher than expected and need to be re-evaluated after 
maintenance of the UPLC® system. 
 
 Accuracy 
This parameter, allows evaluating dispersion of results between dependent tests, 
when repeated for the same sample and under the same chromatographic conditions. It is 
expressed by the CV or RSD obtained by injecting three different concentrations, the low, 
medium and high levels, of the calibration curves. Samples must be analyzed six times on the 
same day (Intra-day) and reproducibility on three non-consecutive days (Inter-day) [245], and 
the calculations with the replicate data of the different concentrations must be performed. 
Additionally, accuracy of an analytical method increases as the value of R2 is closer to 1, 
obtaining a good linear regression [246].  
Within this parameter are the repeatability and reproducibility of methods. In the 
present work and, as reported, it was not possible to obtain them. 
 
 Matrix effect and Recovery 
The matrix effect is determined by the percentage of the ratio between control and 
fortified sample. The recovery can be calculated by the following equation [245]: 
Percent Recovery = 100 x ([Standard Fortified] - [Standard]) / [analyte added] 
 
This study was not conducted, because it was not possible to conclude validation of 
the developed chromatographic methods, neither apply the developed methods to biological 
samples. 
 
An analytical method is also considered applicable when it is specific, selective, and 
when the recovery tests are closer to 100% [226]. More, the calibration curve, the analytical 
linearity and sensitivity of the technique express quantification. Moreover, the method is 
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robust if it proves to be practically insensitive to small variations that may occur when 
performed [224]. 
In our work we were not able to completely validate the methods due to instability of 
the chromatographic system translating into a high variability in peak retention times, areas 
and heights both for the method developed for thiol compounds and for the method for 
purine analysis. Following the specialized technical instructions we eliminated all the possible 
causes presented below [233, 247]:  
i. Incompatibility of the mobile 
phase composition and the samples to 
be analyzed; 
 The solvents used have been widely 
reported as compatible with the intended 
analysis. 
 Several solvents at different ratios were 
tested, the 95% H2O|0.1%FA : 5% ACN being 
chosen, was the most compatible. 
ii. The system is not equilibrated;  The system was allowed to equilibrate 
even up to 2 hours and the results were the 
same.  
iii. Pump pressure or mechanical 
problems; 
 In the first instance, an expert evaluated 
this possibility and found no problem in the 
pump or the system. Further, it was found that 
the chromatographic equipment presented 
problems in the pumps system, requiring 
specialized maintenance. 
iv. Air trapped in the pumps or a 
leak in the system; 
 It was not observed any external leakage. 
Only an expert in UPLC equipment could confirm 
this.  
v. Temperature variations due to 
temperature of the laboratory; 
 This may have caused small variations, 
because the laboratory has no cooling system 
and it was not easy to completely stabilize the 
temperature of the sample manager, especially 
on warmer days. However, it does not explain the 
poor reproducibility obtained. 
vi. Column overloading, as the 
retention time usually decreases as the 
mass of the solute injected exceeds the 
column capacity; 
 It was not considered a problem, because 
it the injection of highly concentrated standard 
samples was always avoided. 
vii. Degradation or contamination of 
the column, that gradually decreases 
the retention time; 
 Tests to check the column status were 
held with good results. See more below. 
viii. Unstable flow-rate;  Flow rate changes were not observed. 
However, it could have happened without being 
identified or reported by the computer system. 
 
As noted above, some tests were held in order to check the column status using a 
quality control solution, supplied by Waters Corporation. The results performed indicated no 
problem with the HSS T3 column used. Also a mixture of certified standards composed by 
acetone, naphthalene and acenaphthene, had been tried previously. The chromatographic 
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results were reasonable in terms of plate count, resolution and tailing factor. See results 
annexed in annex 14.  
In our results, it was possible to verify large peak area fluctuations, when the same 
sample was injected multiple times. There may be many different reasons for this. Nearly 
every part of the UPLC® equipment can conceivably contribute to changes in peaks areas. 
Problems in the injector, which may cause any air bubble formation, result in a random 
variation of the injection volume, from injection to injection. Decreases in peak area from run 
to run, can be caused by temperature changes, but the effect is rather small, under 2% and not 
significant [229]. Random variations of flow-rate can also be a problem, by malfunctioning of 
the check valves and air or cavitations in the pump head. The detector also may contribute to 
peak area variations, but in an indirect way [229]. At one point we questioned, what 
reproducibility of the peak area was reasonably expected? The theoretical information 
indicates that the relative standard deviation of the peak area, for repetitive injections, should 
be less than 1%, where values between 0.2% and 0.5% are excellent [229]. 
The theoretical reproducibility can be increased by using an internal standard and 
calculating the ratio of the peak retention time (or area or height) to the one of the internal 
standard, for each analyte [248]. This was tested in the UHPLC-FLR method, as presented 
below in the table 23 and figure 71 using cysteamine as internal standard.  
 
Table 23 - Ratio of peak retention time, area and height for each thiol analyte with the internal standard 
cysteamine: 
Ratio 
Relative standard deviation 
(%) of the retention time 
Relative standard 
deviation (%) of the area 
Relative standard 
deviation (%) of the height 
GSH/Cyst 1.17 10.33 7.76 
Cys/Cyst 0.09 7.89 4.51 
Hcy/Cyst 0.08 6.94 2.78 
 
Unfortunately, results were mostly above 1%, mainly for peak area and height, 
confirming the above-mentioned problems with the UPLC® system. 
 
Figure 71 - Chromatographic results of injection of a mixture of standard thiols, glutathione, cysteine, 
cysteammine and homocysteine (each 100 µM). 
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4. Conclusions and Future Perspectives 
Thiol compounds are important biomarkers of oxidative stress, and some purines are 
also involved in these processes. However, analysis of thiols constitutes a great challenge due 
to their high instability. 
Since Hopkins discovery, the scientific community has developed numerous methods 
to identify and quantify thiol compounds and their derivatives, in several biological fluids and 
cell extracts. The stability of thiol compounds has been one of the major concerns, since they 
oxidize easily.  
In our work we tried to adapt HPLC conditions from previously reported methods of 
analysis of thiol and purine compounds, to UHPLC. A method with fluorescence detection for 
thiol compounds and another method with photodiode array detection for purine compounds. 
One of our limitations was the avoidance of buffered solutions currently used in HPLC, 
in order to prevent UPLC® technical problems. The use of buffered mobile phase solutions is 
important, mainly for thiols, and it has been reported that these compounds remain more 
stable as they ensure the protection of the sulfhydryl groups, preventing their oxidation [232]. 
Nonetheless, we succeeded in finding a pre-analytical treatment and chromatographic 
conditions, which provided good chromatogram resolutions for the compounds of interest. 
We developed two procedures that are simple, fast and sensitive but they were not 
accurate. Therefore, the validation of these methods has not been completed and the reasons 
were not clear. After several attempts to disclose the problems we came to the conclusion that 
the UPLC® system was having pump problems, what certainly explains the lack of precision of 
our methods. Still, some more time was needed to clarify that matter. 
Optimization of the methods was accomplished. Sample pre-treatment, namely 
derivatization of thiols for UHPLC analysis with fluorescence detection, was successfully 
optimized.  
The mobile phase compositions seemed to be appropriate for the separation of thiol 
and purine compounds but validation needs further analyses to be concluded. Consequently, it 
was still not possible to apply these methods to analysis of biological samples or cell lysates. 
As future perspectives, completing validation of both methods and testing biological 
samples, are the main goals. To find biomarkers that are effective in preventing and 
anticipating pathological conditions related to oxidative stress is another major target.  
In conclusion, besides the difficulties, this work was considered to be a real profit since, 
it allowed the acquisition of a broad knowledge on analytical methods like liquid 
chromatography, which is widely used in several scientific areas of laboratory diagnosis. 
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6. Annexes 
Annex 1 – Chromatographic conditions tested in the UHPLC analysis with PDA and FLR detection for the 
wavelength detection assays: 
UHPLC system testing conditions 
Injection volume 2 µL 
Sample manager temperature 
10 °C 
37 °C 
HSS T3 column temperature 30 °C 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 1 min 
Mobile phase - Isocratic 
95% H2O|0.1%FA : 5% ACN 
90% H2O|0.1%FA : 10% ACN 
 
 
Annex 2  - Testing the reducing agent TCEP·HCl on thiol compounds and UHPLC-PDA analysis: 
UHPLC-PDA testing conditions  
Injection volume 2 µL 
Sample manager temperature 37 °C 
HSS T3 column temperature 30 °C 
Specific UV Wavelength 
detection 
GSH  200 nm 
Hcy  238 nm 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 1 min 
Mobile phase - Isocratic 90% H2O|0.1%FA : 10% ACN 
 
 
Annex 3 – Thiol compounds are not fluorophores: 
UHPLC-FLR system testing conditions  
Injection volume 2 µL 
Sample manager temperature 37 °C 
HSS T3 column temperature 30 °C 
Excitation wavelength 385 nm 
Emission wavelength 515 nm 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 1 min 
Mobile phase – Isocratic  
pH 2.90 
90% H2O|0.1%FA : 10% ACN 
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Annex 4 - Biochemical and molecular characteristics of thiol compounds [Consulted online in: ChemSpider - 
Search and share chemistry http://www.chemspider.com and PubChem - Open Chemistry Database página online 
http://pubchem.ncbi.nlm.nih.gov, last entry 27/07/2016]: 
L-Glutathione (GSH)  
Molecular Formula  C10H17N3O6S 
IUPAC Name 
(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-
sulfanylpropan-2-yl]amino]-5-oxopentanoic acid 
Molecular Weight 307.32348 g/mol 
Hydrogen bond donor count 6 
Hydrogen bond acceptor count 8 
pKa 
 
DL-Homocysteine (Hcy)  
Molecular Formula  C4H9NO2S 
IUPAC Name 2-amino-4-sulfanylbutanoic acid 
Molecular Weight 135.18476 g/mol 
Hydrogen bond donor count 3 
Hydrogen bond acceptor count 4 
pKa 
 
 
 
 
 
 
 
 
 
 
Quantification of Oxidative Stress Biomarkers: Development of a Method by Ultra Performance 
Liquid Chromatography 
July 2016 
 
110 
 
Annex 4 (cont.) - Biochemical and molecular characteristics of thiol compounds [Consulted online in: 
ChemSpider - Search and share chemistry http://www.chemspider.com and PubChem - Open Chemistry Database 
página online http://pubchem.ncbi.nlm.nih.gov, last entry 27/07/2016]: 
L-Cysteine (Cys)  
Molecular Formula  C3H7NO2S 
IUPAC Name (2R)-2-amino-3-sulfanylpropanoic acid 
Molecular Weight 121.15818 g/mol  
Hydrogen bond donor count 3 
Hydrogen bond acceptor count 4 
pKa 
 
Cysteamine (Cyst)  
Molecular Formula  C2H7NS 
IUPAC Name 2-aminoethanethiol 
Molecular Weight 77.14868 g/mol 
Hydrogen bond donor count 2 
Hydrogen bond acceptor count 2 
pKa 
 
L-Homocystine (2Hcy)  
Molecular Formula  C8H16N2O4S2 
IUPAC Name 2-amino-4-[(3-amino-3-carboxypropyl)disulfanyl]butanoic acid 
Molecular Weight 268.35364 g/mol 
Hydrogen bond donor count 4 
Hydrogen bond acceptor count 8 
pKa 
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Annex 5 – Chromatographic columns and pre-columns tested 
Annex 5a- Specifications of the column and pre-column tested, the HSS T3 and BEH C18 from Waters 
Corporation: 
 
  
Name 
ACQUITY UPLC® HSS T3 (2.1 x 100 
mm) column and ACQUITY UPLC® 
HSS T3 VanGuardTM (2.1 x 5 mm) 1.8 
µm particle size 
ACQUITY UPLC® BEH C18 (2.1 x 50 
mm) column and ACQUITY UPLC® 
C18 VanGuardTM pre-column (2.1 x 5 
mm) 1.7 µm particle size 
Part Number 
186003539 
186003976 
186002350 
186003975 
Lot Number 
0167351071 
0166351181 
0234340521 
0233340421 
% Carbon Load 11% 18% 
Bonding Technology T3 --- 
Brand AQUITY UPLC 
Chemistry C18 
End capped Yes 
End Fitting Type 
Waters 
Direct-connect 
Format 
Column 
VanGuard Pre-column 
ID 2.1 mm 
Length 
100 mm 
5 mm 
50 mm 
5 mm 
Mode Reversed-Phase 
Particle 
 
 
 
 
Particle Shape Spherical 
Particle Size 1.8 µm 1.7 µm 
Particle Substrate Silica Hybrid 
Pore Size 100 Å 130 Å 
Silanol Activity 
Low 
Medium 
Low 
Low 
Surface Area 230 m2/g 185 m2/g 
Ligand Density 1.6 µmol/m2 3.1 µmol/m2 
System UPLC/UHPLC 
Technology HSS BEH 
USP Classification L1 
Units in Package 
1/pkg 
3/pkg 
pH Range 2 - 8 1 - 12 
Temperature Limits 
Low pH 45 °C 
and High pH 45 °C 
Low pH 80 °C 
and High pH 60 °C 
Note: Consulted online in: www.waters.com; 
http://www.waters.com/waters/partDetail.htm?partNumber=186003539 ; 
http://www.waters.com/waters/partDetail.htm?locale=119&partNumber=186002350, last entry 27/07/2016. 
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Annex 5b – Assay to choose the optimal chromatographic column for the best separation of thiol 
compounds by UHPLC-FLR method: 
UHPLC-FLR testing conditions  
Injection volume 2 µL 
Sample manager temperature 10 °C 
HSS T3 column temperature 
30 °C 
BEH C18 column temperature 
Excitation wavelength 385 nm 
Emission wavelength 515 nm 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 1 min 
Mobile phase - Isocratic 95% H2O|0.1%FA : 5% ACN 
 
 
Annex 6 – Assay for obtaining optimal chromatographic separation of cysteine, homocysteine and 
homocystine in the UHPLC-FLR method: 
UHPLC-FLR testing conditions  
Injection volume 2 µL 
Sample manager temperature 4 °C 
HSS T3 column temperature 30 °C 
Excitation wavelength 385 nm 
Emission wavelength 515 nm 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 5 min 
Mobile phase – Isocratic 
 pH 2.90 
95% H2O|0.1%FA : 5% ACN 
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Development and optimization of an analytical UHPLC-PDA method for purines analysis by 
UPLC® system   
Annex 8 - Biochemical and molecular characteristics of the analyzed purine compounds [Consulted online 
in: ChemSpider - Search and share chemistry http://www.chemspider.com and PubChem - Open Chemistry 
Database online http://pubchem.ncbi.nlm.nih.gov, last entry 27/07/2016]: 
Adenosine (Ado) 
Molecular Formula  C10H13N5O4 
IUPAC Name 
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-
(hydroxymethyl)oxolane-3,4-diol 
Molecular Weight 267.24132 g/mol 
Hydrogen bond donor count 4 
Hydrogen bond acceptor count 8 
pKa 
 
Inosine (Ino)   
Molecular Formula  C10H12N4O5 
IUPAC Name 
9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-
yl]-3H-purin-6-one 
Molecular Weight 268.22608 g/mol 
Hydrogen bond donor count 4 
Hydrogen bond acceptor count 6 
pKa 
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Annex 9 – Conditions tested in the UHPLC analysis by PDA detection: 
UHPLC system testing conditions 
Injection volume 2 µL 
Sample manager temperature 10 °C 
HSS T3 column temperature  30 °C 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 1 min 
UV Wavelength specific 
detection 
Ado 254 nm 
Ino 250 nm 
Mobile phase - Isocratic 95% H2O|0.1%FA : 5% ACN 
 
 
Annex 10 - Gradient mobile phase tested in adenosine detection on UHPLC-PDA system [223]: 
 
Annex 10a - Chromatogram of UHPLC-PDA detection of adenosine (100 µM) at 254 nm. See 
chromatographic conditions in annex 1a. 
 
Annex 10b - Chromatographic data obtained from separation of adenosine: 
Data 
Retention time Area Height 
Maximum 
Absorvance 
min 
RSD 
(%) 
µV°sec 
RSD 
(%) 
µV 
RSD 
(%) 
AU 
RSD 
(%) 
Ado 1.217 ± 0.000 0.12 233908.52 ± 823.67 0.35 74305 ± 275.67 0.37 0.513 ± 0.000 0.49 
Note: average of two injections. 
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Annex  11 - Gradient mobile phase tested in the UHPLC-PDA system: 
Run time (min) H2O|0.1%FA (%) ACN|0.1%FA (%) 
0 90 10 
0.5 - 1.5 95 5 
2 98 2 
3 90 10 
4 - 5 90 10 
Run time (min) [*] H2O|0.1%FA (%) ACN|0.1%FA (%) 
0 96 4 
0.5 96 4 
2.5 90 10 
5 72 28 
5.1 5 95 
6.1 5 95 
6.2 96 4 
7.5 96 4 
Run time (min) [**] H2O|0.1%FA (%) ACN|0.1%FA (%) 
0 99.9 0.1 
2 98 2 
3.5 70 30 
3.51 5 95 
4.79 5 95 
4.8 99.9 0.1 
6 99.9 0.1 
Note: Gradient mobile phase tested consulted at: [*] Gray N and Plumb R. A Validated Assay for the 
Quantification of Amino Acid in Mammaian Urine. Waters Corporation© 2014, 720005189EN AG-PDF. 
[**] New L and Chan E. Evaluation of BEH C18, BEH HILIC and HSS T3 (C18) Column Chemistries for the 
UPLC-MS-MS Analysis of Gluthione, Glutathione Disulfide and Ophthalmic Acid in Mouse Live and 
Human Plasma. Journal of Chromatographic Science 2008, 46, 209-214. 
 
Annex 12 – Testing methanol as solvent in mobile phase for purine by UHPLC-PDA detection: 
UHPLC-PDA testing conditions  
Injection volume 2 µL 
Sample manager temperature 10 °C 
 HSS T3 column temperature 30 °C 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 1 min 
Specific detection UV 
Wavelength  
Ado 254 nm 
Ino 250 nm 
Mobile phase - Isocratic 90% H2O|0.1%FA : 10% MeOH 
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Annex 13 – Assay to choose the optimal chromatographic column for the best separation of purines 
compounds by UHPLC-PDA method: 
UHPLC-PDA testing conditions  
Injection volume 2 µL 
Sample manager temperature 10 °C 
HSS T3 column temperature 
30 °C 
BEH C18 column temperature 
Flow-rate 0.200 mL/min 
Analysis time 5 min 
Equilibrating time 1 min 
Specific detection UV 
Wavelength  
Ado 254 nm 
Ino 250 nm 
Mobile phase - Isocratic 95% H2O|0.1% AF : 5% ACN 
 
 
 Annex 14 - Quality Control Test on the Chromatographic Column HSS T3 
The goal of this test, it was to indicate that the chromatographic system was functioning as 
expected or outside of expectation.  
The Certificate of Analysis, Waters Neutrals QC References Material (Number 186006360), 
composed by acetone (10 µL/mL), naphthalene (0.25 mg/mL) and acenaphthene (0.4 mg/mL). This 
mixture of standards was injected in the chromatographic system seven times, under the following 
standardized conditions by which the quality of the column is measured. 
 
 Annex 14a - Chromatographic conditions for determining the state of the HSS T3 column: 
UHPLC-PDA Analytic Conditions 
Injection volume 1.2 µL 
Sample manager temperature off 
HSS T3 column temperature 
(100mm x 2.1mm, 1.8µm particle size. Without pre-column) 
30 °C 
UV Wavelength detection 254 nm 
Flow-rate 0.450 mL/min 
Analysis time 6 min 
Rebalancing time 1 min 
Mobile phase - Isocratic 35% H2O : 65% ACN 
 
 
 
 
 
Quantification of Oxidative Stress Biomarkers: Development of a Method by Ultra Performance 
Liquid Chromatography 
July 2016 
 
117 
 
- Chromatographic results: 
 
Annex 14b - Overlap of the seven injections performed with the quality control composed by acetone 
(1º peaks), naphthalene (2º peaks) and acenaphthene (3º peaks). 
 
 It was possible to check with these results, that there is a wide variation in the retention time of 
each compound. The Waters experts report, if the retention time shifts it should be investigated 
problems in the pumping system, in the mobile phase or even some column instability, such as loss in 
bonded phase (Consulted at Waters Corporations. Neutrals Quality Control Reference Material. Waters The 
Sciences of What´s Possible.™ 2013, 18 pages, Ref.: 720004432EN Rev B IH-KP-PDF).  
 
Annex 14c - Chromatographic data obtained in the HSS T3 column status data obtained though 
automatic of integration method:  
Average of 7 injections Acetone Napthalene Acenapthene 
Retention time (min) 0.751 2.483 3.884 
Area (µV°sec) 198936 661402 395312 
Area (%) 15.84 52.67 31.48 
Height (µV) 142734 242947 99202 
USP Plate Count 7.307760e+003 1.972874e+004 2.175556e+004 
USP Resolution --- 3.206020e+001 1.564278e+001 
USP Tailing 1.364202e+000 1.111123e+000 1.050123e+000 
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The number of theoretical plates (N), also known as column efficiency, is a measure of the 
dispersion of a peak. The supplier refers that the columns do not have fixed number of plate counts. For 
a given column, plate counts depend on the flow-rate, the viscosity of the solvents and the molecular 
weight of the analyte. The column manufacturer has set up the standardized chromatographic 
conditions were the mobile phase used contain a high amount of organic solvent, so was low viscosity 
[229]. However, in our case, we are dealing with polar molecules, which require mobile phase with 
higher water content, thus higher viscosity. For this reason, it is natural that in our chromatographic 
analysis the plate count is lower, under the practical conditions establish than under column testing 
conditions.  
 
Observation - Some molecular structures were fulfilled through the HyperChem Release 8.0 Professional 
Software, applying the basic knowledge acquired in Molecular Modelling. It was used Amber99 
programs as Molecular Mechanics force field, which best fits the simulation of proteins. Additionally 
were performed Molecular Dynamics mode to optimize the molecular structure. 
 
 
 
 
